An economic forecasting microsimulation model of the Australian Pharmaceutical Benefits Scheme by Abello, Annie et al.
National Centre for Social and Economic Modelling
 University of Canberra 
AN ECONOMIC FORECASTING
MICROSIMULATION MODEL OF
THE AUSTRALIAN
PHARMACEUTICAL BENEFITS
SCHEME
(VERSION 00-01)
Annie Abello, Laurie Brown,
Agnes Walker and Linc Thurecht
Technical Paper no. 30
November 2003
About NATSEM
The National Centre for Social and Economic
Modelling was established on 1 January 1993, and
supports its activities through research grants,
commissioned research and longer term contracts
for model maintenance and development with the
federal departments of Family and Community
Services, Health and Ageing, and
Education, Training and Youth Affairs.
NATSEM aims to be a key contributor to social
and economic policy debate and analysis by
developing models of the highest quality,
undertaking independent and impartial research,
and supplying valued consultancy services.
Policy changes often have to be made without
sufficient information about either the current
environment or the consequences of change.
NATSEM specialises in analysing data and
producing models so that decision makers have
the best possible quantitative information
on which to base their decisions.
NATSEM has an international reputation as
a centre of excellence for analysing microdata and
constructing microsimulation models. Such data
and models commence with the records of real
(but unidentifiable) Australians. Analysis typically
begins by looking at either the characteristics or
the impact of a policy change on an individual
household, building up to the bigger picture by
looking at many individual cases through
the use of large datasets.
It must be emphasised that NATSEM does not have
views on policy. All opinions are the authors own
and are not necessarily shared by NATSEM.
Director: Ann Harding
National Centre for Social and Economic Modelling
 University of Canberra 
AN ECONOMIC FORECASTING
MICROSIMULATION MODEL OF
THE AUSTRALIAN
PHARMACEUTICAL BENEFITS
SCHEME
(VERSION 00-01)
Annie Abello, Laurie Brown,
Agnes Walker and Linc Thurecht
Technical Paper no. 30
November 2003
ISSN 1443-5098
ISBN 1 740 88145 1
© NATSEM, University of Canberra 2003
National Centre for Social and Economic Modelling
University of Canberra  ACT  2601
Australia
170 Haydon Drive
Bruce  ACT  2617
Phone + 61 2 6201 2780
Fax + 61 2 6201 2751
Email Client services hotline@natsem.canberra.edu.au
General natsem@natsem.canberra.edu.au
Website www.natsem.canberra.edu.au
Title An Economic Forecasting Microsimulation Model of the Australian
Pharmaceutical Benefits Scheme (Version 00-01)
Author(s) Annie Abello, Laurie Brown, Agnes Walker and Linc Thurecht
Series Technical Paper no. 30
Key words microsimulation model; prescribed medicines; pharmaceutical benefits
scheme; Australia; drug costs
iii
NATSEM Technical Paper no. 30
Abstract
In 2001 NATSEM was asked to develop a prototype model of Australias
Pharmaceutical Benefits Scheme (PBS) for the then Australian
Pharmaceuticals Manufacturers Association, now Medicines Australia,
making use of a model built in the late 1990s for the then Department of
Health and Family Services. Towards the end of that year, NATSEM was
awarded an Australian Research Council Linkage Grant, with Medicines
Australia as industry partner, to further improve the model and to
develop within it the facility not only to forecast expenditures and
estimate the distributional effect of the PBS, but also to quantify the
health benefits of future pharmaceutical innovations.
This technical paper documents the current status of the model (version
00-01) and serves as the starting point to examine features of the model
that could be enhanced. It also provides the necessary reference for
developing a facility within the model to quantify the benefits of
improved health outcomes, which would represent a major advance in
modelling the PBS.
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General caveat
NATSEM research findings are generally based on estimated
characteristics of the population. Such estimates are usually derived
from the application of microsimulation modelling techniques to
microdata based on sample surveys.
These estimates may be different from the actual characteristics of the
population because of sampling and nonsampling errors in the
microdata and because of the assumptions underlying the modelling
techniques.
The microdata do not contain any information that enables identification
of the individuals or families to which they refer.
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Abbreviations
ABS Australian Bureau of Statistics
APMA Australian Pharmaceutical Manufacturers Association
C1 Concessional patients that have not reached the safety net
CPI Consumer price index
CSHC Commonwealth Seniors Health Card
CURF Confidentialised unit record files
DALY Disability adjusted life years
DHA Department of Health and Ageing
DVA Department of Veterans Affairs, Australia
G1 General patients that have reached the safety net
G2 General patients that have not reached the safety net
HBC Health Benefit Card
HCC Health Care Card
HIC Health Insurance Commission
HES ABS Household Expenditure Survey, 1993-94 or 1998-99
IMS IMS Health Inc. (where IMS stands for Intercontinental
Marketing Services)
MA Medicines Australia
NHS ABS National Health Survey, 1995 or 2001
PBS Pharmaceutical Benefits Scheme
PCC Pensioner Concession Card
QALY Quality adjusted life years
SFR Self-funded retirees
SNT Safety net threshold
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Explanations
Variable Description
Card Variable indicating that a person (or family) is
entitled to PBS drugs at concessional costs (that is, a
person with a Commonwealth Seniors Health Card,
Health Care Card and/or Pensioner Concession
Card).
Copayments Patients contributions to the total cost of medicines
subsidised under the PBS.
Family An income unit as defined in ABS surveys  a
nuclear family, meaning a couple with dependent
children, a couple without dependent children, a sole
parent with dependent children, or a single person.
In the model, family dependants include all children
aged 014, full-time students aged 1524, and non-
full-time students aged 1520 who did not qualify for
the Youth Allowance but are considered dependants
for Family Tax Benefit purposes. With respect to the
HICs PBS, family dependants include children
under 16 years of age and full-time dependent
students under 25 years of age.
Patient
spending or
contributions
Patient payments at the pharmacy for prescribed
PBS-listed drugs (same as copayment for subsidised
PBS medicines).
Group 1 drugs Drugs with a cost to government under the PBS
(benefit drugs).
Group 2 drugs PBS-listed prescribed drugs not attracting a
government subsidy, or drugs with a total cost or
price below the PBS copayment level (below
copayment drugs).
Group 3 drugs Prescribed drugs not listed under the PBS or private
medicines.
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Variable Description
Safety net
threshold
Total annual amount that individuals and families
pay in a calendar year for PBS-listed drugs at the
regular copayment rate before the patient copayment
per PBS item decreases from the regular rate to the
concessional rate. The safety net protects families
from large overall expenses on PBS-listed drugs.
In 2002 the regular and concessional rates were:
• $22.40 and $3.60 for general patients
• $3.60 and $0 for concessional patients.
Subsidy Government contribution to the cost of PBS drugs.
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1 Introduction
In the late 1990s NATSEM developed a patient-based microsimulation
model for the Pharmaceutical Benefits Branch of the then Department of
Health and Family Services. Documentation for this model  called the
PBS model  is provided in NATSEM Technical Paper no. 15 (Walker,
Percival and Fischer 1998). Policy-relevant applications of that model
have been detailed by Walker, Percival and Harding (2000) and Walker
(2000).1
In 2001 NATSEM was contracted by the then Australian Pharmaceuticals
Manufacturers Association (APMA), now Medicines Australia (MA), to
develop a model of the distributional and economic impact of Australias
pharmaceutical industry and the PBS. The resulting model links a very
detailed new Medicine Module, based on data covering the period 1992
93 to 200001, to an updated and extended version of the original PBS
model, now called the Patient Module. We refer to the model as the MA
model to be consistent with the change in name of the funding
organisation, while reports on earlier versions call it the APMA model.
Starting with the original model, NATSEM successively added the
Medicine Module, revised the drug classification, updated the input
database and the model to 2000-01, and developed a forecasting (up to
five years) capability. This technical paper documents the development
and current status of the model of Australias PBS (version 00-01) that
NATSEM developed for Medicines Australia. Its primary aim is to
document the current status of the patient-based microsimulation
module. The paper also describes features of the current model that need
to be revised or further developed. The aim is to extend the MA model
concerning subsidised prescribed pharmaceuticals into a socioeconomic
model that incorporates health outcomes. This significant advancement
is being funded by a three-year Australian Research Council Linkage
Grant, with Medicines Australia as the industry partner.
The Medicine Module will be the subject of a separate technical paper.
                                          
1 These latter-refereed publications were based on NATSEM Discussion Papers nos
31 and 45.
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2 Overview of the PBS
The Commonwealth Governments Pharmaceutical Benefits Scheme
aims to provide Australians with timely, reliable and affordable access
to necessary and cost-effective prescription medicines. The PBS was
designed originally in 1948 to provide access for all Australians to a free
list of life-saving medicines. Medicines must be approved for use in
Australia and then be assessed as being cost effective in order to be listed
on the scheme. The scheme covers Australian residents and eligible
foreign visitors (unless they are treated in institutions  for example,
hospitals).
Today, a comprehensive range of medicines is listed on the PBS. As at
1 May 2002 the PBS covered 593 drug substances (generic drugs),
available in 1461 forms and strengths (items) and marketed as 2506
different drug products (brands). A restricted listing applies to 785 of the
items, 286 of which require an authority from the Health Insurance
Commission (HIC) for prescribing (for details see the following
website <www.health.gov.au/pbs/general/aboutus.htm>).
Patients are required to make a contribution to the cost of prescribed
medicines listed on the PBS. Individuals and families eligible for certain
federal government (Centrelink) pensions and allowances are able to
access PBS medicines at concessional rates. The PBS also has safety net
arrangements to protect individuals and families from large overall
expenses for PBS-listed medicines. The levels of patient copayments and
the PBS safety net arrangements are referred to as the PBS policy settings.
Patient copayments and safety net thresholds (SNTs) are revised annually
in line with the consumer price index (CPI) from 1 January each year.
Patients may pay more than the copayment if a PBS item is priced above
the benchmark price for different brands of the same drug or the
benchmark price for a particular therapeutic group of drugs. The
government pays the additional cost of drugs exceeding patient
copayments up to the benchmark price only. Brand or therapeutic group
premiums do not count towards safety nets.
Since the early 1990s expenditure on the PBS has grown at more than 10
per cent a year  well above the growth in the health budget (6 per cent)
or the economy (4 per cent in terms of gross domestic product) while
PBS settings in general have increased only in line with inflation.
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Demographic, economic and technological changes are expected to
intensify the pressures on the PBS during the next few decades. The
OECD (2000) notes that in Australia, as in most other developed
countries, real public expenditures per person on pharmaceutical goods
had more than doubled in the previous two decades. In recent budgets
the government has increased the level of contributions to be met by PBS
patients and delisted certain medicines from the Pharmaceutical Benefits
Schedule. Further, the 2002-03 budget aimed to introduce an increase of
close to 28 per cent in PBS copayments and SNTs effective from August
2002 and January 2003 respectively.2
The majority of prescribed drug sales are covered by the scheme and, on
average, the government subsidises patients to the extent of 84 per cent of
PBS drug costs. Currently nearly 80 per cent of total government subsidies
through the PBS accrue to concessional patients  that is, those with the
specified Centrelink cards3  and 20 per cent to general patients.
The policy settings of the PBS for 2000-01, the base year for the model
simulations, are given in table 1. The figures show that:
• for general patients the maximum contribution for each PBS medicine
is $21.90, the government paying for the rest; and
• for concessional patients an additional subsidy applies, so that their
maximum contribution is only $3.50 per PBS medicine.
Although some PBS medicines can cost over $1000 per prescription,
patients are required to pay at most $21.90. If the full price of the
medicine is below $21.90 (or $3.50) the patient pays the full price.
The PBS safety net protects families from high expenditure in any one
year on PBS medicines. Once a family4 that does not have concessional
benefits records spending on PBS medicines beyond the SNT of $669.70 in
a calendar year, they are required to pay only $3.50 for each further PBS
medicine within the same year. For concessional patients there is no cost
                                          
2 These budget measures are currently blocked in the Senate and therefore have not
been implemented.
3 These are the Pensioner Concession Card, the Commonwealth Seniors Health
Card and the Health Care Card. For details, see the relevant Department of Family
and Community Services fact sheets.
4 A family is defined as including a spouse (or de facto spouse), children under 16
years of age and full-time dependent students under 25 years of age.
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once their families have a record of spending beyond the SNT of $182.00
in a calendar year. In this case the government pays the full price of all
further PBS medicines prescribed within the year. Each year on 1 January,
each familys expenditure on PBS-listed prescribed medicines is reset to
zero for administrative purposes.
Table 1 Policy settings of the Pharmaceutical Benefits Scheme, 2000-01
1 January 2000 1 January 2001
$ $
Copayment  concessional
Below safety net threshold 3.30 3.50
Above safety net threshold 0 0
Copayment  general
Below safety net threshold 20.60 21.90
Above safety net threshold 3.30 3.50
Safety net threshold  concessional 171.60 182.00
Safety net threshold  general 631.20 669.70
Source: Department of Health and Ageing, <www.health.gov.au/pbs/pbs/copayment.htm>.
3 Conceptual structure of the model
The MA model version 00-01 is made up of an econometric Medicine
Module and a microsimulation Patient Module (figure 1).
The Medicine Module projects the total number of scripts and the
average cost per script for 19 drug classes, and trends in these data serve
as inputs to the forecasting version of the Patient Module.
The Patient Modules main input dataset is at the person level (that is,
each record is for an individual with links between family members),
with data on drug usage across 36 drug classes5 by gender, age and card
status. The unit of analysis can be the individual, the family or more
aggregate levels (for example, groups by income ranges and/or drug
classes). In forecasting mode, the scripts data in the person-level dataset
are revised each year to be consistent with the aggregate level of scripts
estimated in the Medicine Module.
                                          
5 The Patient Module was built to have 36 drug classes. The first 18 drug classes in
the Medicine Module correspond to the first 18 drug classes in the Patient Module,
while the 19th drug class in the Medicine Module was disaggregated into 18
additional drug classes in the Patient Module.
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Figure 1 Components of the MA model
Medicine Module
Scripts and average cost data by 19
drug classes
Patient Module Part A
Person-level data including data on
drug usage and disposable income
Patient Module Part B
(forecasting model)
Generates forecasts of PBS scripts
and expenditures
Individual-level data on demographic, socioeconomic and drug usage
patterns for the models base year (2000-01) were constructed using
several sources and covering several years. Data from these sources were
then consolidated and aged or uprated to the base year. A second dataset
on the costs of the pharmaceuticals used was then prepared, using the
average per script costs observed administratively for each of the drug
classes in that year. The cost data were then merged onto the patient-
based dataset, allowing estimation of the costs of the drugs used by each
individual in the Patient Module. By aggregating individual-level costs
the model is able to estimate total patient and government expenditures
on prescribed PBS drugs over the base year. These aggregates were
aligned to match actual administrative data on PBS scripts for 2000-01.
In forecasting mode the module can project PBS scripts and expenditures
for five years (2001-02 to 2005-06).
3.1 Overview of the Medicine Module
The Medicine Module is based on data provided by the Health Insurance
Commission on monthly government expenditure and scripts between
January 1992 and June 2001 for all items listed on the PBS. It was also
constructed taking into account data derived from the Pharmaceutical
Benefits Schedule that provides information on policies that apply to
drugs under the PBS. Because the HIC data have information on whether
each script was purchased by a concessional or a general patient, we
were able to estimate patient-level expenditure.
Drug classes were classified by therapeutic class for the Medicine
Module by mapping, first, the HIC PBS codes to the anatomical
6 A Microsimulation Model of the PBS: Version 00-01
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therapeutic chemical (ATC) codes and, second, the ATC codes to the 19
forecast groups used in the Medicine Module. The concordance schedule
is given in appendix A.
Regression equations were constructed for both the average cost and
script data for each of the 19 forecast groups. The regressions were based
on monthly HIC data for the period January 1992 to June 2001, these
data being provided via Medicines Australia. The Medicine Module
provides five-year forecasts (from July 2001 to June 2006) for each
forecast group, using a monthly forecast interval. The predictive
statistical and policy variables included in the module are in table 2.
Table 2 Variables used in the Medicine Module forecast regression
equations
Variable Description
Trend Trend variable
Seasonality Eleven dummy variables representing month of the year
TGP A single dummy variable representing Feb 1998 (groups 5, 7, 8, 13 only)
Copay A single dummy variable representing Jan 1997 (script only)
MolEntry Count variable representing entry of new molecules (as provided by
Medicines Australia)
BioEqGen Count variable representing entry of bioequivalent molecules (as
provided by Medicines Australia)
Authorities & Restrictions Major events only, represented by dummy variables:
Group 1  Dec 1992
Group 2  Apr 1995
Group 6  Nov 1997 and May 1998
Group 8  Dec 1994
Group 12  Nov 1996
Group 13  Dec 1994
The aim was to keep the Medicine Module simple in terms of the
predictive variables used in the forecast regression equations and, where
possible, the functional form of the regression models. For example,
interaction terms have been excluded, and the Authority Required (AR)
and Restricted Listing (RL) variables have been applied to only certain
forecast groups/therapeutic classes and are dummy variables associated
with significant changes in the listing/prescribing requirements for the
forecast groups/therapeutic class. The two policy variables used in the
Medicine Module are MolEntry (molecule entries) and BioEqGen
(bioequivalent molecules). The definition of and data for these two
variables were provided by Medicines Australia. The data series contain
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actual data for January 1992 to June 2001 and were extrapolated to June
2006 in the following ways.
• For molecules, the series increases in July of every forecast year by
the average annual increase over the previous five years.
• For bioequivalence, a new bioequivalent count is registered each time
a patent expires.
As noted in section 1, a separate technical paper is planned for the
detailed description of the Medicine Module.
3.2 Overview of the Patient Module
Stage 1  Creating the main input dataset
Four main sources of data were used to prepare the input dataset for the
Patient Module.
• Individual records were derived from the 2001A version of
STINMOD6 based on the 1998-99 Household Expenditure Survey
(HES) by the Australian Bureau of Statistics (ABS). The variables
extracted included a range of demographic and economic indicators
such as age, gender, family structure, after-tax family income and
concessional (card) status under the PBS.
• The ABS 1995 National Health Survey (NHS) was used to derive
information on the use of prescribed pharmaceuticals across the 36
drug classes, by age, gender and concessional (card) status.
• Weekly household expenditure on prescribed pharmaceuticals was
obtained from the ABS 1998-99 Household Expenditure Survey,
which was merged onto the STINMOD dataset.
• Administrative data on PBS scripts and costs across the 36 drug
classes came from the HIC time series collection (see appendix B).
The process of combining the datasets is outlined in figure 2. The four
data sources were combined at the unit-record level  that is, the
                                          
6 STINMOD is NATSEMs static microsimulation model that models the impact of
the personal income tax and social security systems on Australian families
(Lambert et al. 1994).
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combined dataset is comprised of individuals, each described by a set of
pooled relevant characteristics.
Figure 2 Combining the NHS, STINMOD, HES and HIC datasets
1995 NHS
2001 STINMOD
(output)
1998-99 HES
Group number and types
of drug consumed by
gender, five-year age
group and card status.
Add HES data on weekly
spending on prescribed
drugs, and select only
those with positive
spending.
Create data records for
children.
Extract weekly spending
on prescribed drugs.
2000-01 HIC
(scripts)
Main input dataset
Impute number and type
of drugs used by gender,
age and card status from
NHS onto STINMOD
output, allocating more
scripts to persons with
higher drug spending.
Align model with 2000-01
HIC scripts (revise scripts
per person so aggregates
match HIC numbers).
The STINMOD output dataset formed the main dataset on which the
Patient Module is based. It was important for that dataset to contain a
separate record for each adult and child, since PBS medicine usage by
age group and drug type was a key output expected from the MA
project. However, links between families also had to be maintained since
the PBS rules regarding SNTs concerned total expenditures by families
on prescribed drugs.
Thus the MA models population database is the household sample from
the non-institutionalised Australian population (from the HES) who
spent on prescribed medicines7, plus a proportion of households with
                                          
7 To select persons/families who had spent on prescribed drugs, HES data on
weekly spending on prescribed drugs were merged onto the STINMOD output
A Microsimulation Model of the PBS: Version 00-01 9
NATSEM Technical Paper no. 30
concessional safety net status. That is, a proportion of families with
concessional card status that did not spend on prescribed drugs were
included in the dataset to represent concessional cardholders that had
reached the safety net. For the most part, however, the models
population database excludes individuals (and their families) that had
no expenditure on prescribed drugs. It also excludes people living in
institutionalised care  for example, hospitals and nursing homes.
Prescribed drug usage figures at ages above 70 years, therefore, are
likely to be underestimates.
Adding indicators on script usage from the NHS was more difficult as
the individuals interviewed for the NHS were different from those
interviewed for the HES. Individuals in STINMOD and the NHS were
first classified by gender, five-year age group and card status (2 x 16 x 2
= 64 groups) (see appendix C). The number and types of drug consumed
by each of these 64 groups were then imputed from the NHS to the
Patient Modules main dataset. This was done within each card, age and
gender cell by imputing the number of drugs used (from one drug to a
maximum of seven drugs) and then the types of drug used (from among
36 drug classes). As a result, each person in the Patient Module had one
or more of the 36 drug types allocated to them, so that within each card,
age and gender cell the drug usage pattern in the model matched the
usage pattern in the NHS.
The process of imputing the number of drugs was done differently for
general and concessional patients.
• For general patients, individuals within each cell were ranked by
family expenditure on drugs from highest to lowest. First, seven
drugs were allocated to persons with the highest expenditure until
the weighted share for that cell was equal to the weighted share for
the same cell in the NHS dataset. Then, six drugs were allocated, and
so on, with one drug allocated last.
• For concessional patients, the allocation proceeded randomly within
each cell until the NHS shares had been reached. Expenditure was
not used in the allocation process since concessional patients that
have reached the SNT pay nothing for drugs they consume.
                                                                                                                                   
file. This was a simple matter as the two data files contained the same individuals
(since the version of STINMOD we used was HES-based).
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Finally, the dataset was further modified such that total number of
scripts by the 36-drug classification (based on data on script usage
imputed for each individual using prescribed drugs) was consistent with
HIC data on actual scripts for the base year 2000-01. While aligning the
model to administrative data in this way, the pool of prescribed
medicine was separated into three groups:
• Group 1 scripts for drugs with a cost to government under the PBS
(known elsewhere as benefit drugs);
• Group 2 scripts for PBS-listed prescribed medicines not attracting a
government subsidy  that is, scripts with a total cost (or price)
below the PBS copayment level (below copayment drugs); and
• Group 3 scripts for prescribed drugs not listed under the PBS (private
medicines).
Note that, because the alignment process needs to be carried out against
observed administrative data, it was only done once for the base year
(2000-01). Then throughout the forecasting period, the group assignment
of each observation is assumed to remain unchanged. Consequently, the
alignment process needs to be carried out before the model can be run
for purposes of simulating base year or scenario options.
Stage 2  Simulating the PBS and forecasting scripts and expenditures
Once the main person-based dataset of the Patient Module had been
prepared, the PBS was modelled by applying the rules of the scheme to
each individual (or family) in the dataset. Basically, the Patient Module
uses, as input, an individual (or family) based dataset describing
peoples pattern of usage of 36 types of PBS drug categories, as well as
the average cost of each of these categories. It then simulates
expenditures by patients and the government under the PBS, applying
the rules of the scheme to each individual or family separately over an
18-month period on a two-weekly basis starting on 1 January (when each
familys expenditure on prescribed medicines is reset to zero, which
allows patient spending to accumulate from a zero base).
Results are aggregated for four groups of patients  concessional
patients above the SNT (C0), concessional patients below the SNT (C1),
general patients above the SNT (G1) and general patients below the SNT
(G2)  for the last twelve months of the simulation. This enables
A Microsimulation Model of the PBS: Version 00-01 11
NATSEM Technical Paper no. 30
outcomes to be presented for a full financial rather than a calendar year
for the concessional and general groups.
Briefly, the steps carried out within the second stage of the Patient
Module for the base year involve:
• allowing users of the model to specify the policy settings of the
scheme (copayment levels and SNTs over the simulation period for
concessional and general patients);
• simulating the scheme by computing the costs associated with the
scripts imputed to individuals (based on the average cost per script
for each of the 36 drug classes8) and identifying below and above
SNT patient expenditures for concessional and general patients;
• computing government contributions as total costs less patient
contributions; and
• creating detailed output datasets for concessional and general
patients.
The same process is carried out to generate scripts and expenditures for
the forecast years (2001-02 to 2005-06) except that, instead of using actual
data on scripts and average costs, the model reads in estimated data on
scripts and costs based on trends of aggregate scripts and costs (the sum
for concessional and general patients) as generated by the Medicine
Module for each of the 36 drug classes.
A schedule of all the SAS programs developed to create the database and
run the model for the base year and forecast years is shown in figures 3
and 4.
Because of our reliance on survey data, difficulties were encountered in
fully modelling the effects of the safety net. To compensate for this, the
proportion of scripts beyond the SNTs is constrained in the model to be
equal to the actual share reached in the base year based on
administrative data, on a calendar year basis. This results in accurate
cost estimates by drug type.
                                          
8 The current version of the model uses as input average costs for C0, C1 and G1
patients and G2 patients separately. In actuality there is only one set of average
costs for all types of patient, but this distinction was made to separate out the G2
patients, who pay a higher copayment rate and shoulder a greater proportion of
the price of PBS-listed medicines.
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Figure 3 MA model control program, base year
PROG 4.SAS
1. Extract household expenditures on
prescribed drugs from HES and add
this variable to STINMOD adults.
2. Add 014 year olds to main dataset (so
children have the same CARD indicator
and drug spending as their parents).
Input [allkid]
[age15to]
[hes98exp]
[hes98psn]
Output [ALL]
PROG 3.SAS
1. Identify income units with concession
cards (PCCRD, CSHCCARD, HCCRD)
and potential self-funded retirees
(POTSFR1, POTSFR2).
2. Create individual records for persons
15 years or older.
Input [stin_pbs]
[hes98hsh]
Output [age15to]
PROG 2.SAS
Create individual records for children in
STINMOD.
Input [stin_pbs]
Output [allkids]
PROG 1.SAS
Run STIN01a version of STINMOD and
generate output file.
Input Various STINMOD files
Output [stin_pbs]
PROG 5.SAS
Reproduce NHS extract as close to
original extract as possible but based on
revised drug classification of MA.
Input [NHS95]
Output [FinalExtract1b]
PROG 6.SAS
Read in NHS extract.
Input [FinalExtract1b]
Output [PBS]
PROG 7.SAS
1. Limit the number of CSHCCARD = 1
consistent with Centrelink numbers.
2. Impute number and type of drugs from
NHS to main dataset, by age group and
sex, for all persons with positive
expenditure on prescribed drugs and
for a certain percentage of cardholders
with no expenditure on drugs.
Input [ALL]
[PBS]
Output [stinPBS_St2]
PROG 8.SAS
Create a variable identifying the 100 000
self-funded retirees after the change in
eligibility for the CSHC in January 1999.
Input [stinPBS_St2]
Output [stinPBS_St2]
(Continued on next page)
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Figure 3 MA model control program, base year  (continued)
PROG 13.SAS
Generate output tables on scripts, costs and spending on drugs as a proportion of income.
Input [Drg&year.c]
[Drg&year.g]
Output scr_cost_age.csv
scr_sex.csv
spending.csv
age_fam_dist.csv
PROG 9.SAS
Read the script information
for card and general patients
from HIC data and align the
imputed script distributions
for card and general patients.
Input [stinPBS_St2]
[2000-01scripts
alignment data.CSV]
Output [stinPBSb_St2] 
may have more than
one record per
person if the person
belongs to more
than one group.
PROG 10.SAS
Read HIC data on the
average cost of PBS drugs
for [C0], [C1] & [G1] and for
[G2].
Input [2000-01scripts
alignment data.CSV]
[stinPBSb_St2]
Output [base&year]
PROG 11.SAS
Read in PBS settings on
copayments and safety net
thresholds.
Input PBS settings for
base year
Output [User&year]
PROG 12A.SAS
Run model and generate PBS costs for
cardholders.
Input [User&year]
[base&year]
Output [Drg&year.c]
PROG 12B.SAS
Run model and generate PBS costs for
non-cardholders.
Input [User&year]
[base&year]
Output [Drg&year.g]
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Figure 4 MA model control program, projections 200106
PROG 20.SAS
Generate output tables on scripts, costs and spending on drugs as a proportion of income.
Input [Drg&year.c]
[Drg&year.g]
Output scr_cost_age.csv
scr_sex.csv
spending.csv
age_fam_dist.csv
PROG 14.SAS
Create a variable identifying the 32 000
self-funded retirees after the change in
eligibility for the CSHC in July 2001.
Input [stinPBSb_St2]
Output [stinPBSc_St2]
PROG 19A.SAS
Run model and generate PBS costs for
cardholders.
Input [User&year]
[base&year]
Output [Drg&year.c]
PROG 19B.SAS
Run model and generate PBS costs for
non-cardholders.
Input [User&year]
[base&year]
Output [Drg&year.g]
PROG 18.SAS
Read in PBS settings on copayments and
safety net thresholds.
Input User-specified PBS settings for
base year
Output [User&year]
PROG 17.SAS
Add data on average costs to main dataset.
Input [cost&year.csv]  cost data from
Medicine Module
[scr&year]
Output [base&year]
PROG 16.SAS
For every forecast year, scale up number of imputed prescribed drugs [DTYPE1
DTYPE36] based on growth in scripts between the base and the forecast year.
Input [scrp&year.csv]  scripts data from Medicine Module
[rewt&year]
[stinPBSc_St2]
Output [scr&year]
PROG 15.SAS
Generate revised person weights for every
forecast year; uprate income.
Input [stinPBSc_St2] for forecast years
Output [rewt&year]  with 3 variables only on
PERS_ID WTP DISPINCU
A Microsimulation Model of the PBS: Version 00-01 15
NATSEM Technical Paper no. 30
An important output of the model, in addition to the script and cost
information, is an indicator of expenditure on PBS medicines by poor
and rich Australian families. This is a particular strength of the
microsimulation approach, since distributional issues are much harder to
handle with other types of model. However, at this stage of the models
development we were able to estimate only PBS medicine patient
expenditures as a proportion of disposable income (at the level of the
family) in a notional 114 January window  when expenditure on
prescribed medicines has just been reset to zero. What cannot be
obtained at this stage is a yearly estimate of a particular familys (or an
income-based group of families) expenditure as a proportion of their
after-tax income.
4 Improvements made on the original model
4.1 Database
Household Expenditure Survey 1998-99
The original Patient Module, which was based on the 1993-94 HES, was
upgraded using the confidentialised unit record files (CURF) of the
1998-99 HES. The 1998-99 database comprises 6892 household records
and 13 964 person records. Person records exist for only individuals aged
15 years or over, although limited information on children aged less than
15 years (for example, the number of children per household) is included
within the household data. Expenditure data were collected on over 600
items, one being prescribed medicines. At the expenditure level, there
are a total of 545 613 records in the HES 1998-99 dataset (ABS 2000).
Where possible, the ABS has maintained comparability in the concepts,
classifications and methodology used in the 1998-99 HES with those
from the 1993-94 survey.
National Health Survey 1995
The original model was based on an extract by the ABS from the full
1995 NHS dataset. The extract was purchased by NATSEM, as the unit
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record NHS files were not available at that time. The extract contained
13 942 records.
In the updated model, the drugs have been grouped in a different way to
accommodate the classification adopted for the Medicine Module. This
reclassification required the creation of a new extract from the unit
record files of the 1995 NHS. This extract contains 18 782 records (having
removed from the NHS CURF respondents who did not use prescribed
medicines).
A number was assigned to each medicine type linking the NHS drug
classes to an ATC code and to the 36 drug classes used in the Patient
Module. (The first 18 are the same as in the Medicine Module, and the
remaining 18 classes, when aggregated, are the same as the forecast
group 19 of the Medicine Module.) Note that the NHS does not
specifically identify all the medicines by the ATC codes required for the
MA forecast groups. Profiles of medicine usage for forecast groups that
fall into this category therefore were created based on all other
medicines and actual proportional use, as advised by Medicines
Australia. As per the original Patient Module, the extract is truncated to
read in only the first seven medicines used per NHS respondent.
Two modifications needed to be made to the new NHS extract: one to
discount Department of Veterans Affairs (DVA) cardholders and the
second to assign concession cardholder status to eligible children.
DVA cardholders
The extract totals in the new NHS dataset were higher than in the
original ABS extract as DVA cardholders were excluded from the
original extract. However, DVA cardholders cannot be separately
identified in the NHS CURF. This is because the survey question on
DVA status  available to the ABS when preparing the original extract
 was excluded from the CURF for reasons of confidentiality. We
therefore adjusted the extract to remove the effect of DVA respondents.
To do this, the weight attached to each record (wtp) was deflated. The
deflator was calculated as the weighted total from the original extract
divided by the weighted total in the new extract. When the deflated
weight was applied to each record, the number of medicines used and
number of cardholders were reduced accordingly.
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Children
Initially, there were no children aged less than 15 years in the NHS
extract with a positive cardholder status. Children whose parents had a
concession card were not identified in the NHS CURF as being
cardholders themselves. Thus, the extract had to be modified so that
children aged less than 15 years could have the same card status as their
parent/s. This adjustment resulted in 624 children changing card status.
The variables contained in the final version of the NHS95 extract used in
constructing the MA model are given in table 3.
Table 3 Variables in the NHS95 final extract
Variable name Description
Sex Sex of person:
1 = male;
2 = female
Pers_id Unique person identifier
Inc_id Unique income unit or family identifier
NewAge (renamed to Age_PBS) 5-year age grouping (116):
1 = 04 years
2 = 59 years
3 = 1014 years
4 = 1519 years
5 = 2024 years
6 = 2529 years
7 = 3034 years
8 = 3539 years
9 = 4044 years
10 = 4549 years
11 = 5054 years
12 = 5559 years
13 = 6064 years
14 = 6569 years
15 = 7074 years
16 = 75 years and above
Cardholder Whether person holds a concession card:
0 = no
1 = yes
Rev_ Cardholder (renamed to Card) Whether adults in family hold a concession card:
0 = no
1 = yes
(Continued on next page)
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Table 3 Variables in the NHS95 final extract  (continued)
Variable name Description
Med1 First type of drug by Patient Module bin
Med2 Second type of drug by Patient Module bin
Med3 Third type of drug by Patient Module bin
Med4 Fourth type of drug by Patient Module bin
Med5 Fifth type of drug by Patient Module bin
Med6 Sixth type of drug by Patient Module bin
Med7 Seventh type of drug by Patient Module bin
Q614 0 = med1 not prescribed, 1 = med1 prescribed
Q625 0 = med2 not prescribed, 1 = med2 prescribed
Q636 0 = med3 not prescribed, 1 = med3 prescribed
Q647 0 = med4 not prescribed, 1 = med4 prescribed
Q658 0 = med5 not prescribed, 1 = med5 prescribed
Q669 0 = med6 not prescribed, 1 = med6 prescribed
Q680 0 = med7 not prescribed, 1 = med7 prescribed
NumMedUsed (renamed to MedCount) Number of prescription drugs used
Wtp (renamed to wtp_nhs) Deflated person weight variable for this extract file
STINMOD/01A
The current MA model uses the output data file of STINMOD/01A. The
original model used the output data file of STINMOD/96A. The latter
version of the model was based on the 1993-94 HES and reflected the
federal government income support payments and income tax systems
as they were in 1996. Since that time, however, the tax reform package A
New Tax System has been implemented and the more up-to-date
1998-99 HES data have been released. Hence, STINMOD/01A reflects
the income tax and social security systems as they were in the 2000-01
financial year, and is based on the 1998-99 HES. It is the output dataset
from this version of STINMOD that has been used in the current version
of the MA model.
This derived dataset contains 8653 income unit records. Income unit
records exist only for family heads aged 15 years or more.
An individual record for each adult and child within each income unit
was generated from the STINMOD/01A database.
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4.2 Changes to the Patient Module
Key tasks
The following tasks were undertaken in updating the model:
• adjustment of the Patient Modules drug groupings to match the 19
forecast groups used in the Medicine Module;
• reconstruction of the Patient Module database, updating to the
1998-99 HES and the related STINMOD files (uprated to 2001);
• realignment of the model to the 2000-01 HIC PBS script and cost data;
and
• testing plus validation of the base year results for the upgraded
Patient Module.
Drug classification and concordance
The drug classification for the Patient Module was arranged so that it
aligned with the first 18 forecast groups in the Medicine Module (that is,
the first 18 groups were kept intact  neither disaggregated nor
combined with another medicine forecast). The 19th forecast (residual)
group was allocated across the remaining 18 bins available in the Patient
Module. This disaggregation was decided by Medicines Australia.
The basis of the split for the residual 18 bins was initially the ATC type
 keeping the B*s together (blood and blood forming organs medicines),
keeping the remaining M*s together (musculoskeletal system medicines
excluding forecast Group 1), etc. However, because this did not result in
36 classes, some ATC types were further divided. For example, the
remaining cardiovascular drugs were divided into three classes  20, 21
and 22. This disaggregation produced bin sizes that were large enough
to generate non-zero results from the Patient Module.
When extracting drugs based on the new classification from the NHS,
the NHS drugs used classes of 25, 27 and 99 were split between the 18
bins based on the actual proportional usage of drugs included in these
bins in 1999-00 as advised by Medicines Australia.
The final classification of medicines used in the Patient Module is given
in table 4.
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Table 4 Drug classes used in the Patient Module
As a proportion ofDrug
class Description Government cost Patient cost Scripts
% % %
1 Anti-inflammatories 1.26 1.75 3.05
2 Asthma medications 7.70 8.16 7.00
3 Diabetes medications 3.58 1.78 2.51
4 Vasodilators & beta blockers 2.60 2.71 4.48
5 ACE inhibitors 6.86 10.83 7.15
6 Angiotensin IIs 1.70 3.24 1.84
7 Calcium channel blockers 4.68 6.45 5.53
8 Cholesterol & triglyceride reducers 14.91 10.97 7.03
9 Analgesic medications 2.50 3.51 6.50
10 Antipsychotics 3.61 1.05 1.42
11 Anxiolytics & hypnotics 0.88 2.50 4.66
12 Antidepressants 6.53 9.34 5.95
13 Stomach medications 9.98 9.09 6.69
14 Antibiotics 4.07 5.74 8.24
15 Antineoplastics 6.12 0.90 0.55
16 Genitourinary 3.09 3.52 4.38
17 Anti-epileptics 2.08 1.46 0.99
18 Direct acting antivirals 1.81 0.55 0.19
19 Decongestants & antihistamines 0.57 1.04 0.95
20 Cardiac glycosides & anti-arrhythmics 0.45 0.55 0.71
21 Antihypertensives 0.39 0.50 0.60
22 Fluid & diuretic medications 0.80 1.13 1.99
23 Vitamin & mineral supplements 1.01 0.65 1.03
24 Cough & cold medications 0.10 0.14 0.25
25 Skin ointments & creams 1.97 1.86 2.11
26 Laxatives 0.26 0.22 0.39
27 Other medication  alimentary tract &
metabolism (excluding diabetes &
stomach medications) 1.93 1.90 1.66
28 Other medication  blood & blood forming
organs 1.23 1.34 2.16
29 Other medication  systemic hormonal
preparations (excluding sex hormones) 0.60 1.06 1.52
30 Other medication  general anti-infectives
(excluding antibacterials & antivirals) 0.65 0.49 0.55
31 Specific antirheumatic agents 0.05 0.03 0.02
32 Other musculoskeletal system
medications  topical products, muscle
relaxants, antigout & bone disease 1.26 0.73 0.98
33 Other medication  antimigraine,
psychostimulants & neotropics, anti-
Parkinson & parasympathomimetics 0.96 0.71 0.86
34 Other medication  antiparasitic products,
insecticides & repellents 0.27 0.48 0.73
35 Other medication  sensory organs 2.14 2.84 4.45
36 Other medication  various 1.27 0.54 0.58
Note: See appendix A for Drug Concordance PBS and ATC codes.
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Changes to variables
The SAS coding was revised in all programs in the database creation and
alignment phase of the Patient Module to correct for changes to data
items included in the HES, STINMOD and NHS input datasets. Key
changes are now described.
Expenditure on prescribed drugs (HES)
Two particular changes to the HES dataset, at the expenditure level,
should be noted. First, a key change to the 1998-99 HES database was the
introduction of the household expenditure classification that replaced
the HES commodity code list used in previous surveys. The household
expenditure classification is a five-level hierarchical classification, items
at the most detailed level such as prescriptions, being represented by a
10-digit code rather than the 3-digit commodity code value used in the
1993-94 HES.
In the 1993-94 HES the expenditure item code (for variable COMCODE)
for prescriptions was 459, for which there were 2201 (0.3 per cent)
records. This represented 1 645 915 persons whose households spent on
prescribed drugs or 24.9 per cent of the population. In the 1998-99
survey, prescriptions were coded under the variable COMCOD10, as
item number 0903010101. There were 2108 (0.4 per cent) record counts,
representing 2 025 008 persons or 28.4 per cent of the population.
Second, the data item identifier for expenditure value was changed. In
the 1993-94 HES dataset, expenditure value was represented by the
variable EXPVALUE. In the 1998-99 survey, this was relabelled to
SUMEXP.
Other definitional and data item changes in the 1998-99 HES were
indirectly incorporated into the Patient Module through the
STINMOD/01A database since this version of STINMOD was based on
the 1998-99 HES.
PBS concessional patients (STINMOD)
Important changes to the variables and SAS code in the Patient Module
had to be made to reflect changes in the definition and eligibility of
individuals and families to federal government pensions and
allowances. Centrelink now issues three types of concession and health
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care cards that allow cardholders access to PBS medicines at the
concessional rate. These are the Pensioner Concession Card, the Health
Care Card and the Commonwealth Seniors Health Card. The Health
Benefits Card previously issued to sickness allowance beneficiaries,
which was included in the initial Patient Module, no longer exists and
has been deleted from the revised module code.
The uprated STINMOD database incorporates changes to the federal
government pension and allowance schedules. The eligibility criteria for
the three health concession cards were checked against Centrelink
documentation. Potential cardholders were then identified using the
STINMOD/01A revised variable classifications and Centrelinks
updated income thresholds.9 With the abolition of the Health Benefits
Card, individuals receiving a sickness allowance are now eligible to
apply for the Health Care Card, and thus were included in the revised
coding for this group of cardholders.
Automating the alignment procedure
The pattern of drug usage from the 1995 NHS by sex and age group was
imputed onto the 2000-01 MA model base data. As the data in the 1995
NHS covered all prescribed drugs, there was a need to select from this
group a subset representing drugs attracting a government contribution
under the PBS. This was done by aligning the scripts in the 2000-01
model to the scripts appearing in the HIC 2000-01 data (grouped into the
same 36 drug classes as the Patient Modules base data). The alignment
was carried out separately for concessional and general patients.
In the previous version of the model, the script alignment was done by
hand and for only total scripts (for example, a 10 per cent fit at the
aggregate level was considered adequate). Moreover, particular drug
groups with a low volume of scripts were represented as having zero
scripts.10 For the current 2000-01 model, NATSEM automated the
                                          
9 For reasons explained in section 5.3 (on concession cardholders) we opted to
identify Commonwealth Seniors Health Cardholders using pre-January 1999
income thresholds.
10 This occurred when the script usage of the first observation in the dataset using
that particular drug group exceeded the HIC fortnightly scripts for the same
drug group.
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alignment process and carried out the alignment separately for each of
the 36 classes. The result is that we were able to exactly match the actual
number of scripts in the HIC data. Script numbers were aligned for every
year from 2000 to 2006 so the script forecast of the Medicine Module was
exactly equal to the script output of the Patient Module for each of the 36
drug classes. Through a modification in the input dataset and alignment
procedure, there were no longer any drug classes having zero scripts.
This was done by creating multiple observations, with each observation
having a proportionally smaller weight. The smaller weight was
calculated by taking the original weight divided by the number of
multiple observations created.
The fit for costs is not as good as for scripts, in part because the ratio of
above-SNT scripts to total scripts remained modelled only at the
aggregate level. Considerable changes to the SAS program would be
required to consider this ratio at the 36 drug class level so as to obtain a
better fit.
Handling drugs dropping out of the PBS
As the model covers only PBS-subsidised drugs, in the original PBS
model when the average price of a drug fell below the copayment, the
drug dropped out of the model and the associated scripts and costs
were no longer counted. This feature of the model posed problems when
formulating alternative scenarios wherein the price of some drugs fell
below copayment. In such cases, the model would stop counting the
associated scripts and costs and results were not comparable with the
base case. For example, if a particular scenario raised the copayment
such that some drugs dropped out of the PBS, one would expect patient
costs to increase but in some cases there was a decline in patient costs as
a result of drugs dropping out of the PBS.
To address this problem, Medicines Australia requested that NATSEM
continue to count in all drugs even when the settings in a particular
scenario would have caused some to drop out of the PBS. NATSEM
revised the code such that all scripts and costs were counted in but
additional tables were generated on the proportion of drugs dropping
out of the PBS that had been counted in.
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5 Focus on the Patient Module
5.1 Summary of key model constructs
• The MA model predicts script numbers and expenditure only for
prescribed drugs subsidised under the PBS (defined in the modelling
as Group 1). It does not include prescribed drugs whose prices fall
below the PBS copayment levels (Group 2) or prescribed drugs not
listed on the PBS (Group 3).
• The models population database is a sample of households from the
non-institutionalised Australian population who spent on prescribed
medicines plus a selection of households with concessional card
status who did not spend on prescribed medicines, included to
represent those with concessional safety net status.
• For each of the 36 drug classes, expenditure is computed as
(scripts)*(average cost) and is expressed in current dollars.
• The model is able to provide annual forecasts.
• The base case represents the situation where no policy changes
occur (except CPI indexed copayment increases).
• The input script and cost data to the Patient Module (for the base and
forecast years) are obtained from the Medicine Module.
5.2 Computation of input script and cost data
The script and cost data used in the base case forecasts (and scenarios)
were derived by applying annual growth rates predicted by the
Medicine Module to the Patient Module base year data  the HIC
2000-01 administrative data.
Aggregate script numbers and total costs for each of the 36 drug classes
used in the Patient Module were obtained from the Medicine Module for
each of the forecast years. The average cost of each drug class was
computed for each forecast year. The total number of scripts and the
average cost for each medicine bin for each forecast year were then
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compared with the respective base year figures, and the growth rate
between the base and forecast year determined.
Script numbers and average costs, split into concessional and general
components, were then obtained for each forecast year by applying the
growth rates to the base year script and average cost figures for
concessional and general patients for each drug class. That is, the base
year concessional and general numbers were adjusted, year by year, in
line with the aggregate growth rate forecast within the Medicine
Module. Thus the numbers of concessional and general scripts for each
drug group have the same growth rate, as do concessional and general
average costs for each drug group.
5.3 Uprating the population base
Concession cardholders
From 1 January 1999 the federal government raised the income
thresholds for self-funded retirees eligibility to the Commonwealth
Seniors Health Card (CSHC). The CSHC reduces the cost of prescription
medicines for Australians of Age Pension age, but who do not qualify
for the Age Pension (dependants of CSHC holders are not eligible for
concessions using the cardholders card).
From 1 January 1999 self-funded retirees qualified for the CSHC if they
had an annual income of:
• less than $41 000 for singles  increased from $21 000; or
• less than $68 676 combined for couples  increased from $34 000.
Centrelink indicated that they expected about 220 000 additional self-
funded retirees to qualify for the CSHC and a take-up rate of about 50
per cent. Based on these numbers, NATSEM estimated that there would
be about 100 000 additional CSHCs held by self-funded retirees as a
result of this policy.
From 1 July 2001 the federal government again raised the income
thresholds for self-funded retirees eligibility to the CSHC. Self-funded
retirees qualified for the CSHC if they had an annual income of:
• less than $50 000 for singles  increased from $41 000;
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• less than $80 000 combined for couples  increased from $68 676; or
• less than $100 000 combined for couples who are separated due to ill
health.
These limits are increased by $639.60 for each dependent child cared for
and the level of this allowance did not change.
Centrelink identified that these changes increased the number of CSHC
holders by approximately 31 760 individuals.
When incorporating these policy changes into the model, we had to take
into account the fact that the input datasets on which the model was
based were all pre-1999. Income thresholds prior to January 1999 were
applied to check eligibility of potential CSHC holders (CSHCCARD)
prior to January 1999. Two variables identifying potential self-funded
retirees for the first and second policy changes were created (POTSFR1
and POTSFR2) based on income, age and sex criteria.11
Based on the pre-January 1999 income thresholds, the model originally
had about 46 000 CSHC holders. The 100 000 and 32 000 self-funded
retirees based on the two policy changes were initially considered as
non-cardholders. The effect of this was that these retirees were imputed
the drug usage of non-cardholders. There is a large difference in drug
usage between concession cardholders and non-cardholders, with
concession cardholders having about 60 per cent more scripts per person
each year than non-concession cardholders. Thus, in later stages of
creating the base data for the model, these self-funded retirees were
transferred from the non-cardholders group to the concession
cardholders group.12 Since the pool of potential cardholders (POTSFR1 =
1 and POTSFR2 = 1) was greater than 100 000 and 32 000 respectively,
self-funded retirees were selected from the pool of potential cardholders
on a random basis.
                                          
11 For males the cut-off age is 65 years while for females it is 62.5 years. Since the
age variable in the model is a categorical variable representing five-year age
groups, for females we chose those aged 60 or more rather than 62.5 or more.
12 The database stinPBSb_St2 (for 2000-01) had about 146 000 CSHC holders while
stinPBSc_St2 (for 200106) had about 178 000 CSHC holders.
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Population projections
The Patient Modules population was uprated year by year over the
forecast period in line with the ABS five-year agesex group projections.
The ABS population projections were scaled down so that the population
represented only people who lived in households and who bought
prescribed drugs.
The ABS population projection figures for the five-year agesex groups
were obtained from the ABS publication catalogue series 3222.0. The
ABS produces alternative projections of the resident population of
Australia based on different assumptions about fertility, mortality and
migration. Figures from Series1a13, the high growth series, were used.
To derive the household population that bought prescribed drugs, each
of the agesex cells was scaled  first, by the proportion of the resident
population living in private dwellings (with the proportion assumed to
have remained unchanged from the 1993-94 HES) and, then, by the
percentage of each five-year agesex group in the household population
that bought prescribed drugs as identified from the 1998-99 HES data.
Next, the growth rates between the base year (2000-01) and successive
years in the scaled projected populations were calculated. These rates
were then applied to the Patient Modules base year population to derive
target forecast year populations. The target five-year agesex groups
for each of the forecast year populations were then entered into the
software package CALMAR to derive new person weights. Finally, the
modules population was uprated by changing the person weights
(originating from the 1998-99 HES) to those generated by CALMAR.
The forecast year 2001-02 is the financial year July 2001 to June 2002; the
other years are also financial years. Since the ABS calculates its
population projections as at 30 June, we use the ABS population data for
30 June 2001 for the first forecast year, and so forth for the other years,
ending with 30 June 2005 for the forecast year 2005-06.
The age distribution of the models population (Group 1 patients) for the
base year (2000-01) and the 2005-06 forecast year is given in figure 5. The
most notable feature is the growth in numbers in the 55 years or more
age groups.
                                          
13 Assuming a fertility rate of 1.75 births per woman and net overseas migration of
110 000. (One mortality rate assumption is used for all series.)
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Figure 5 Model populations: spenders on PBS subsidised prescribed
drugs, 2000-01 (base year) and 2005-06 (base case forecast)
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Family incomes
The Patient Modules population database was also uprated to reflect
likely increases in family disposable incomes. A uniform rate of change
in income, regardless of income level, was assumed. Since growth in
gross domestic product is expected to be lower in the next few years
than in the recent past, it is reasonable to adopt the relatively
conservative trend growth in male average weekly earnings rather than
growth in the mean gross weekly income. Mean gross weekly income
increased on average by 4.4 per cent a year over the past five years while
average weekly earnings increased by 3.07 per cent a year during the
years 199101. Family disposable incomes were uprated by the growth
factor in average weekly earnings.
5.4 PBS copayment and safety net threshold settings
In addition to updating concessional status, NATSEM uprated the PBS
policy settings  copayments and SNTs  to the settings that came into
effect from 1 January 2001.
Projections of PBS settings for the forecast period were made by uprating
current PBS settings in line with expected changes in the CPI. Given that
there seems to be no reason why CPI changes over the next few years
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should diverge markedly from longer term trends, we assumed for the
base case forecasts that copayments and SNTs will increase by 2.5 per
cent a year  the percentage change in the CPI from the September
quarter of 2000 to the September quarter of 2001 and over the previous
10 years.
The levels of copayment and the SNTs for the base year were given in
table 1. Assuming a growth rate of 2.5 per cent a year from 1 January
2001, the copayment reached by 1 January 2006 is $3.96 for concessional
patients below the SNT and $24.77 for general patients below the SNT.
The SNT is $205.91 for concessional patients and $757.70 for general
patients.
We also assumed that the proportion of total scripts of families whose
script costs were allowed to reach the SNT would remain at the 2000-01
(base year) levels throughout the forecasting period  that is, at 20.38
per cent for concessional patients and 18.93 per cent for general patients
on a calendar year basis.14 These proportions were based on PBS data
provided by HIC on the actual number of scripts per patient category.
5.5 Presentation of results
Standard tabulations are generated for the base year, for each of the
forecast years of the base case and, where appropriate, for alternative
scenarios on the following:
• scripts and costs (patient, government and total) for 36 drug classes
for concessional, general and all patients;
• scripts, patient costs and government costs by five-year age groups of
concessional and general patients;
• scripts by gender and 36 drug classes for concessional and general
patients;
                                          
14 The safety net operates on a calendar year basis and therefore needed to be
modelled within this period. To reconcile this with the need to generate statistics
on a financial year basis, the safety net was modelled over an 18-month period
and statistics were based on scripts and costs for the financial year or the last 12
months. For alignment purposes, the proportion of families reaching the SNT in
the last 6-month period was restricted to 0.5 of 20.38 per cent for concessional
patients and 0 per cent for general patients.
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• family spending on subsidised PBS drugs as a share of family
disposable income, by income quintile, for concessional and general
patients that use PBS-subsidised drugs; and
• distribution of concessional and general patients that use PBS-
subsidised drugs by age of family head, family type and income
quintile.
6 Model validation
6.1 Comparing imputed and original script distribution
One of the most complex tasks in developing the model was imputing
script usage from the NHS onto the models input dataset. As stated, this
was done by first imputing the number of drugs used (from one drug to
a maximum of seven drugs) and then the types of drug used (from
among 36 classes).
With respect to the first part of the imputation process, figure 6 shows
that the distribution of the number of drugs used per person in the
models input dataset for all prescribed drugs, closely matches the
original distribution for both general and concessional patient groups.
6.2 Comparing the Medicine Modules output with the Patient
Modules output on aggregate scripts and costs
The models output on aggregate scripts and costs was also validated. The
output of the Patient Module for total scripts and patient and government
costs (for both concessional and general patients) for the base year and
forecast years was compared with output of the Medicine Module. This
was done because in the previous version of the model, only scripts (at
the 36 drug group level) for the base year were aligned with data
generated by the Medicine Module. Data on scripts for the forecast years
were also read in from the Medicine Module but, because of differences in
individual person weights in the forecast years15, the aggregate number
of scripts generated by the Patient Module for the forecast years did not
                                          
15 Individual person weights vary across the forecast years to reflect population
ageing across time.
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correspond exactly with the number of scripts forecast by the Medicine
Module.
Table 5 shows that the Patient Module is able to replicate total scripts (as
well as scripts for each of the 36 drug classes) as forecast by the Medicine
Module. However, it is less accurate with respect to replicating total
costs as forecast by the Medicine Module. It underestimates patient costs
for concessional patients by 4 percentage points, and overestimates
patient and government costs for general patients by 7 and 10 percentage
points respectively. The reason for the lack of consistency in costs
generated by the modules is differences in average cost breakdown. In
the Patient Module C+G1 average costs were used for the concessional
group, and G2 costs for the general group. The justification is that G1
Figure 6 Distribution of the number of medicines used per person,
National Health Survey and imputed
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patients (general patients that have reached the SNT) pay the lower
copayment rate charged concessional patients.
The Medicine Modules output is very close to actual figures for 2000-01.
Therefore the comparison of Patient Module output with actual figures
follows the same pattern.16
As with the base year, total scripts (as well as its breakdown for each of
the 36 drug classes, although not presented here) for the forecast years
are replicated exactly (table 6). For the forecast years, total costs (the total
of patient and government expenditures) generated by the Patient
Module also compared favourably with the output of the Medicine
Module (the ratio being 1.02 and 1.03 over the forecast years).
                                          
16 We had to choose between using actual data from the HIC or DHA. (There is
some inconsistency between HIC and DHA figures.) Both organisations generate
data on PBS scripts and government costs, although DHA also generates data on
patient costs. While the MA model relied mainly on HIC data inputs, we opted to
use DHA actual data in table 5 so that a comparison could be made of both
government and patient costs. Had we used HIC data, the fit between the
models output and actual data would have been even closer.
Table 5 Base year: Patient Module output, Medicine Module output and
actual data compared
Unit
Patient
Module
output
Medicine
Module
output
Actual
data
Patient Module:
Medicine Module
Patient Module:
Actual data
Concessional
Scripts 000 124 121 124 121 124 705 1.00 1.00
Patient cost $000 323 737 336 811 337 378 0.96 0.96
Government cost $000 3 044 146 3 019 895 3 019 946 1.01 1.01
Total cost $000 3 367 883 3 356 707 3 357 324 1.00 1.00
General
Scripts 000 22 686 22 686 22 866 1.00 0.99
Patient cost $000 436 103 405 549 406 784 1.07 1.07
Government cost $000 871 558 790 269 790 270 1.10 1.10
Total cost $000 1 307 662 1 195 818 1 197 054 1.09 1.09
Concessional and general
Scripts 000 146 807 146 807 147 571 1.00 0.99
Total cost $000 4 675 545 4 552 525 4 554 378 1.03 1.03
Sources: MA model output; Department of Health and Ageing
<www.health.gov.au/pbs/pubs/HICexp/pbjun/book02.htm>.
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Table 6 Forecast years: Patient Module and Medicine Module output
compared
Patient Module
output
Medicine Module
output
Patient Module:
Medicine Module
Scripts 000 000 ratio
2000-01 146 807 146 807 1.00
2001-02 148 018 148 018 1.00
2002-03 151 316 151 316 1.00
2003-04 156 017 156 017 1.00
2004-05 161 028 161 028 1.00
2005-06 166 686 166 686 1.00
Total cost $000 $000 ratio
2000-01 4 675 545 4 552 525 1.03
2001-02 4 934 234 4 806 629 1.03
2002-03 5 191 677 5 058 557 1.03
2003-04 5 577 435 5 438 334 1.03
2004-05 5 971 422 5 826 390 1.02
2005-06 6 216 991 6 065 888 1.02
Source: MA model output.
6.3 Validation against change in PBS settings announced in 2002
As the key function of the model is to be able to examine the
implications of policy changes, it is crucial that the model produces
reliable and accurate results when running scenarios. It should be
acknowledged that the credibility of any model depends on the
reliability of the input data and the construction of the model. The
validity of the outcomes of the scenarios is subject to both the use of
appropriate data and the capacity within the Medicine and Patient
modules to make the necessary policy changes. The accuracy and
reliability of the model can be tested and validated by simulating, for
example, the projected outcomes from changes in the PBS settings as
announced in the 2002 federal budget.
Simulation results by the model therefore were compared with expected
outcomes from PBS-related policy changes announced in the 14 May
2002 federal budget. The government proposed increasing the levels of
patient copayment for both concessional and general patients by
approximately 28 per cent. The announced new PBS settings are listed in
the table 7. If these proposed changes had been passed by the Senate, the
rise in copayments was due to come into effect on 1 August 2002 and the
increase in SNTs on 1 January 2003. When announcing the new policy
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settings, the related changes were estimated to result in about $1056
million in net savings to government17 over the following four years
(Treasury 2002).
Table 7 Copayment and safety net thresholds at 1/1/2002 and as per
budget announcement effective on 1/1/2003
Actual
1/1/2002
Budget proposal
1/1/2003
$ $
Copayment  concessional
Below safety net threshold 3.60 4.60
Above safety net threshold 0 0
Copayment  general
Below safety net threshold 22.40 28.60
Above safety net threshold 3.60 4.60
Safety net threshold  concessional 187.20 239.20
Safety net threshold  general 686.40 874.90
The above policy change was simulated using the MA model, assuming
that after January 2003 that the increases in PBS copayments and
thresholds would be in line with the expected increases in the CPI of 2.5
per cent a year. The results of the simulation were compared with the
base case where PBS settings increased in line with annual CPI growth of
2.5 per cent. Government expenditures for the financial year 2002-03 as
currently generated by the MA model are lower than expected.18 We
corrected for this by using scripts forward one year19, and fixing the
proportion of families reaching the SNT at 21 per cent for concessional
patients and 20 per cent for general patients for all forecast years. As a
result of these changes, the model estimate of total PBS government
expenditure for 2001-02 was virtually identical to the budget estimate
and for the period 200206 the model estimates closely approximated
government estimates  within 5.5 per cent (table 8).
                                          
17 These are the savings to the Department of Health and Ageing portfolio from
changes in the PBS settings. Further savings of $59.7 million accrue to the
Department of Veterans Affairs through savings from the Repatriation
Pharmaceutical Benefits Scheme.
18 There were unanticipated increases (blow-outs) in script volumes and costs for
some specific drug items.
19 The number of scripts per drug group in 2006-07 was estimated by applying the
growth rate for 2004-05 to the number in 2005-06. The average cost per drug
group in 2005-06 was assumed to be unchanged in 2006-07.
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Table 8 Savings to government from changes in PBS settings as
announced in the 2002 federal budget
Unit
2001-02
base data 2002-03 2003-04 2004-05 2005-06 Total
Budget estimates
Total govt expenditure $m 4 379.0 4 311.0 4 641.0 5 015.0 5 394.0 19 361.0
Concessional $m 3 479.0 3 522.0 3 803.0 4 102.0 4 420.0 15 847.0
General $m 900.0 789.0 838.0 913.0 974.0 3 514.0
Savings $m 284.3 266.4 256.9 247.9 1 055.5
Estimated change in
govt expenditure % -6.2 -5.4 -4.9 -4.4 -5.2
MA model estimates
Total govt expenditure $m 4 382.0 4 501.6 4 803.8 5 020.3 5 104.0 19 429.8
Concessional $m 3 358.9 3 511.6 3 746.8 3 881.2 4 003.0 15 142.6
General $m 1 023.1 990.0 1 057.0 1 139.1 1 101.0 4 287.2
Savings $m 208.5 240.0 199.7 278.2 926.4
Estimated change in
govt expenditure % -4.4 -4.8 -3.8 -5.2 -4.6
Focusing on the effect of the policy on government expenditures, the
proposed 28 per cent increase in copayments is expected to result in
overall savings to the government of 45 per cent in each of the simulation
years. The savings would be smaller for concessional patients (3 per cent
for all years) than for general patients (713 per cent). For general patients,
the estimates for the last two years of the simulation involve dropping out
certain drug groups prescribed to general patients, as the average cost of
these drug groups fell below the copayment level. They dropped out
because such drugs were no longer eligible for government assistance
under the PBS.20 With no drug dropping out, the savings on general
patients would have been greater  at 1114 per cent.
In summary, for both concessional and general patients over the four
years of the scenario, the simulations show government costs declining
by $926.4 million relative to the base case. This is lower than, but not too
far off from the estimate of $1055.5 million in the budget papers. The
estimated savings to government of 46 per cent based on budget
estimates is slightly lower than the 45 per cent based on MA model
                                          
20 This involved ACE inhibitors (drug class 5), angiotensins (drug class 6) and
calcium channel blockers (drug class 7) whose average prices fell below the
copayment for general patients of $30.05 starting in January 2005 and $30.80
starting in January 2006.
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estimates. Differences in assumptions may have widened the gap
between budget estimates and those generated using the model. For
instance, there is a marked decline in budget figures on government
expenditure on general patients in 2002-03 that may be due to some
assumptions about price response that had not been factored into the
MA model.
Apart from assessing the accuracy of the models output on government
expenditure, the validation exercise also points to the need to check the
models assumptions on scripts and average prices per drug group for
the simulation years, in order to be able to more closely target actual or
expected government expenditure. It also highlights the need to examine
the proportionality between estimates of expenditures on concessional
and general patients. For example, model estimates of government
spending on general patients exceed budget estimates by 25 per cent for
nearly all forecast years. In contrast, model estimates of government
spending on concessional patients are virtually the same in 2002-03, but
fall behind gradually to 91 per cent of budget estimates by 2005-06.
Two additional examples of standard output from the model for the base
year and final forecast year of the scenario (28 per cent increase in PBS
settings) are presented in table 9 and figure 7. Table 9 shows the total
number of scripts and the total costs for each of the 36 drug classes and
figure 7 shows the proportion of family income spent on PBS-subsidised
drugs by the general patient population who used these drugs.
As mentioned, a particular strength of the microsimulation approach is
its capability to generate an indicator of the affordability of PBS
medicines to poor and rich Australian families. Figure 7 shows the type
of distributional information that the model is able to provide. The
general patient population using PBS-listed and subsidised drugs ranked
by disposable (after-tax) family income is divided into five equal groups
or income quintiles, and shows the proportion of each groups income
being spent on PBS-subsidised drugs in January 2001 and January 2006.
In preparing the figure, as described previously, PBS copayments were
assumed to increase by about 28 per cent, with the rise in copayments
coming into effect on 1 August 2002 and the increase in safety net
thresholds on 1 January 2003. We further assumed that increases in PBS
settings in subsequent years would be in line with inflation, while
income was assumed to increase in line with the expected growth of
male average weekly earnings.
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Table 9 Scripts and costs: 2000-01 (base year) and 2005-06 (scenario, 28
per cent increase in PBS settings)
Description Scripts Total costsDrug
class 2000-1 2005-6 Change 2000-1 2005-6 Change
000 000 % $ million $ million %
1 Anti-inflammatories 6 744 7 363 9 241 250 4
2 Asthma medications 9 804 9 734 -1 334 370 11
3 Diabetes medications 3 810 5 634 48 169 261 55
4 Vasodilators & beta blockers 6 339 6 094 -4 113 109 -3
5 ACE inhibitors 10 029 8 539 -15 290 215 -26
6 Angiotensin IIs 4 329 5 458 26 125 116 -7
7 Calcium channel blockers 7 387 6 824 -8 187 157 -16
8 Cholesterol & triglyceride reducers 11 313 23 373 107 658 1 265 92
9 Analgesic medications 9 249 9 729 5 122 143 17
10 Antipsychotics 2 027 2 233 10 158 311 97
11 Anxiolytics & hypnotics 6 419 6 571 2 47 48 2
12 Antidepressants 9 494 14 051 48 391 577 47
13 Stomach medications 9 334 12 343 32 386 494 28
14 Antibiotics 11 287 8 904 -21 182 158 -13
15 Antineoplastics 887 1 247 41 275 599 118
16 Genitourinary 6 277 6 246 0 146 155 6
17 Anti-epileptics 1 426 1 634 15 83 111 34
18 Direct acting antivirals 276 324 17 63 80 28
19 Decongestants & antihistamines 672 1 350 101 12 39 216
20 Cardiac glycosides & anti-arrhythmics 982 1 013 3 19 25 31
21 Antihypertensives 789 860 9 15 22 50
22 Fluid & diuretic medications 2 652 2 841 7 34 50 48
23 Vitamin & mineral supplements 1 402 1 471 5 37 42 14
24 Cough & cold medications 336 351 4 4 6 38
25 Skin ointments & creams 2 938 3 005 2 84 101 21
26 Laxatives 564 556 -1 10 12 14
27 Other medication  alimentary tract
& metabolism 2 024 2 367 17 70 98 40
28 Other medication  blood & blood
forming organs 3 569 3 084 -14 89 69 -22
29 Other medication  systemic
hormonal preparations (excluding
sex hormones) 2 166 2 167 0 30 46 50
30 Other medication  general anti-
infectives 766 783 2 25 28 12
31 Specific antirheumatic agents 22 28 29 1 2 38
32 Other musculoskeletal system
medications 1 496 1 391 -7 57 50 -11
33 Other medication  antimigraine,
psychostimulants & neotropics, anti-
Parkinson & parasympathomimetics 1 264 1 222 -3 43 42 -2
34 Other medication  antiparasitic
products, insecticides & repellents 1 018 1 040 2 12 19 55
35 Other medication  sensory organs 6 473 6 347 -2 99 125 27
36 Other medication  various 1 241 833 -33 63 45 -28
All 146 807 167 013 14 4 676 6 241 33
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Figure 7 shows at the family level that the poorest general patients who
used PBS-subsidised drugs (quintile 1) are most affected financially by
Australias PBS system. In 2000-01 they are estimated to have spent 6.5
per cent of their families disposable income21 on PBS-subsidised drugs
(7.6 per cent by 2005-06), compared with 2.3 per cent on average for all
patients (general and concessional). In summary, the simulations show
that these families spend 78 per cent of their after-tax family income on
PBS-listed prescribed medicines, which is considerable, even though it is
only part of the families total expenditure on health. The group of
poorest general patients includes families with incomes just above the
levels needed to qualify for PBS concessional status  for example, large
families (three or more children) with parents in low skilled and/or non-
permanent jobs, with three-fifths of family heads aged 4064 years.
Figure 7 Proportion of family income spent on PBS subsidised drugs by
general patients who used PBS medicines, January 2001 and
January 2006
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Note: The proportion of family income spent was measured over the fortnight 114 January (see pp. 15 and
4244 for discussion on modelling the safety net). Quintiles refer to disposable cash incomes computed for the
prescribed drug user population subsidised under the PBS (that is, they are not quintiles for the whole Australian
population).
                                          
21 Average family disposable income was calculated after setting negative incomes
to zero. In this example, we chose to set the negative incomes in the models main
dataset (arising from the HES) to zero. The issue of negative incomes in surveys
is a much researched area (see Walker and Abello 2000, sections 3.1 and 6). As a
result, the average income level of quintile 1 general patients increases somewhat
compared with the original survey incomes.
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For all quintiles, the proportion of family income spent on PBS drugs in
114 January 2006 was higher than in 114 January 2001 because the
expected rate of increase in drug spending (that depends on increases in
script numbers and PBS copayments) was higher than the expected rate
of increase in incomes.
7 Capability and limitations of the Patient Module,
and future enhancements
While much work has been undertaken in the past year to upgrade the
model, there is still scope for both minor improvements and major
advancements to the model. This section of the paper analyses various
features of the model, with emphasis on the models current capability
and limitations. It presents possible areas in which the model could be
further developed and enhanced with respect to various technical
aspects of modelling and expanded into a broader field of policy and
research on pharmaceuticals in general and the PBS in particular. The
work needed in scoping and implementing the possible changes to the
model form the basis of the research planned for the Australian Research
Council Linkage Grant.
7.1 Minor model improvements
Rescaling the weight of observations
In the model, scripts are the product of unit scripts per person,
multiplied by the weight of that person in the dataset (the WTP
variable). Depending on the script numbers for the drug and the weight
of the person, some drugs may be represented by only one record or
individual if the script volume is low and the weight of the person is
high. For some drug groups laxatives (drug class 26), other medication
for blood and blood-forming organs (drug class 28) and antirheumatics
(drug class 31)  among general patients, the script volumes were so
low and the weights of the potential individuals consuming those drug
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types so high that, if adjustments had not been made, these drug classes
would have had zero representation.22
One remedy for the above is to revise the weights of some observations
in the dataset such that the weight of each observation or record is, for
example, 100 instead of ranging from 20 to over 7000, and to create
multiple observations for the records whose weights had been rescaled,
so that aggregate figures such as those on population size and drug
usage do not change.
Such a procedure would also have the additional benefit of simplifying
the alignment procedure because the adjustment procedure of sorting
observations by drug group by their weight (from lowest to highest)
could be dispensed with. This adjustment procedure had the unintended
effect of selecting observations with lower weights and resulted in
higher scripts per person for the concessional group relative to previous
years. Further, it would facilitate using a distributional approach to
pricing as such an approach would require several observations per
drug group. The main drawback to rescaling the weight of observations
would be the longer processing time involved.
Using a distributional approach to drug pricing
Patient and government expenditures on the Patient Module drug classes
are currently estimated using the average price of each drug class as
generated by the Medicine Module. For each of the 36 drug classes, the
average price is computed as the total expenditure on PBS prescribed
drugs in that drug group divided by the total number of corresponding
scripts:
Average price = total expenditure / no. of scripts
= ∑wi pi/∑wi
where
wi = no. of scripts for drug subgroup i, i = 1 to n and n = no. of
subgroups;
                                          
22 Adjustments were made such that these three drug classes were represented in
the model with only one individual recorded as consuming each drug, with the
weight of each individual being a fraction of its original weight.
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pi = average price of drug subgroup i; and
∑wi = total no. of scripts for all drug subgroups.
Average prices for specific drugs (for example, Amoxillin capsules of a
given dosage) would be the same for all patient types. However, average
prices for drug classes, an aggregation of various specific drugs
categorised into one group, may vary across different patient types
depending on the composition and cost of specific drugs within each
drug group.
For most drug groups, there is a significant difference between the
average prices for concessional and general patients, the average price for
general patients being significantly higher for most drug groups. The
major reason for this is not differences in consumption (or that general
patients consume the more expensive drugs), but rather the difference in
scope or definition. Recall that the PBS data cover only PBS prescribed
drugs. Since general patients have a much higher copayment rate, lower
cost drugs whose average price falls below the copayment rate for general
patients are not included in the PBS data, whereas these are included for
concessional patients whose copayment rate is much lower. (When we
reach the stage in building the model that all prescribed pharmaceuticals
are included rather than just PBS or government prescribed
pharmaceuticals, we expect to see an evening out of average prices for the
concessional and general groups as the copayment rate would cease to be
a factor restricting the inclusion of drug subgroups for general patients.)
Two different sets of average prices are read in by the Patient Module 
one set of average prices for C0, C1 and G1 patients and another set of
average prices for G2 patients.
C0 patients pay nothing for drugs they consume. C1 and G1 patients pay
the lower copayment rate for concessional patients, while G2 patients
pay the copayment rate for general patients. We chose to aggregate C0,
C1 and G1 patients since the average price they pay per drug group is
not too dissimilar. G2 patients are classified into another group since the
average price they pay per drug group is much higher.
The use of average prices in the MA model is justified on the basis of
simplicity. As we move from a simple model to a more complex one, one
option to better approximate reality is to input a distribution of prices for
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each of the 36 drug classes (at a greater level of disaggregation) rather
than use the average price per drug class.
For example, antihypertensives (drug class 21) had an average price of
$26.79 in 2000-01. This is composed of three subgroups:
ATC code Average price (Pi) % scripts (wi/∑wi)
CO2A $27.98 47.2%
CO2C $25.26 51.3%
CO2D $50.45 1.5%
While the present model produces accurate results at the aggregate level,
some drug groups do drop out of the model in scenarios where the
average price falls below the simulated copayment levels for general
patients. For example, a 22 per cent increase in copayments would cause
all of drug class 21 to drop out. This weakness of the model would be
overcome by incorporating the price distributions within drug groups in
the model. With the price distribution instead of average prices in the
model, we would retain CO2A and CO2D or about half of drug class 21.
In conclusion, the incorporation of a set of prices rather than one average
price would overcome to some extent the dropping out of some drug
groups in the model in scenarios where the average price for that drug
group falls below simulated copayment levels for general patients.
If a particular drug type is represented by only one observation, the
resulting distribution of drug consumption will not be close to actuality.
Thus the adoption of the distributional approach to drug pricing needs
to be implemented hand in hand with the rescaling weights option.
Updating script and cost data (updating the Medicine Module)
The Medicine Module database will be updated by including the actual
HIC data (PBS script and cost data) for the period July 2001 to June 2002.
7.2 Major enhancements
Modelling the safety net
Currently, the proportion of the total number of scripts that reach the
SNT is a user-specified variable in the model, with the default (defined
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separately for general and concessional patients) being the actual
proportion reached in the base year 2000-01.
The SNT is modelled at the family level. Two conditions specified in the
model for a family to reach the SNT are that the familys drug expenditure
reaches the SNT and that the share of total scripts of families that have
already reached the SNT does not exceed the default value specified.
Given that these conditions relate to both costs and the number of
scripts, there needs to be some consistency between model inputs
relating to these.
Due to reliance on survey data, difficulties were encountered in fully
modelling the effects of the safety net. This was because the safety net
rule applies to the total spending on PBS medicines by a family in a
calendar year. However, data on the drugs used during a year by a
particular family are not available. Instead, all that is available is the
two-week sample of drug use provided by the NHS.
To derive annual estimates, the standard practice is to multiply the two-
week figures by 26. For most purposes this provides fairly reliable
estimates, but it is not adequate for modelling the PBS safety net. For
chronic conditions (when drugs are used regularly throughout the year),
multiplying the NHS two-weekly figures by 2623 should give a fair
estimate of annual drug consumption. For non-chronic conditions,
multiplying by 26 would give correct aggregate estimates within the
agesexcard cells but overestimate drug consumption for individuals
and families. Thus, families consuming drugs for non-chronic conditions
may incorrectly be shown to reach the safety net when the consumption
of such drugs should have been spread over several families, none of
whom may have reached the safety net.
As a result, the current version of the model constrains the proportion of
scripts beyond the SNTs to that available from administrative data. This
results in aggregate cost estimates by patient type that closely
approximates actual figures for the base year.
                                          
23 Based on preliminary analysis of annual patterns of drug usage, 13 seems to be
the more realistic factor as the majority of scripts cover a 30-day supply of the
prescribed drug.
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Most of the scenarios specify either a proposed change in copayment
levels or drug prices. Such changes are likely to involve changing the
number of families reaching the SNTs. While for the base case the model
can be run without changing the SNT-related information, this is not
necessarily so when running the scenarios. The user would need to
specify the likely change in the proportion of scripts reaching the SNT
following the changes in copayments, etc. that are being simulated
(Walker, Percival and Fischer 1998, pp. 2731).
The model could be modified so that it would be able to simulate
changes to the safety net features of the PBS. To do this, first its
population base would need to be extended from the prescribed drug
users identified in the two-week window covered by the NHS to all
prescribed drug users in the population over a full year. Also, there
would need to be a distinction between drugs for chronic conditions and
non-chronic conditions. Finally, data on annual rather than fortnightly
drug usage would be required.
With these modifications, there would be no need to constrain the
proportion of scripts beyond the SNTs or the likely change in the
proportion of scripts reaching the SNTs following changes in
copayments that are being simulated. Further, the analysis of patient PBS
medicine costs as a proportion of disposable income, by income quintile,
need not be restricted to the 114 January window. We would then
expect lower PBS spending as a proportion of family incomes in the
revised model, because the same number of scripts would be spread
across more families. As a result, a lower proportion of families would
reach the SNTs.
A review of actual data on the proportion of families reaching the SNTs
shows that this varies across the different drug classes. This factor
should be considered in modelling the SNTs in order to more closely
approximate actual costs incurred. (The current model is able to align
(match) scripts in the base year model with actual HIC statistics by each
of the 36 drug classes, but expenditures are not as closely matched.)
Incorporating elasticities of demand
Each scenario is based on static (non-behavioural) modelling. We assume
no patient response (behavioural change) to any changes proposed in
copayment rates or prices. Other than being a standard practice in
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microsimulation modelling, it is reasonable to make this assumption as
we have no real world data on how patients react, and therefore to date
have not been able to build reliable estimates into the model.
NATSEM has run some scenarios incorporating price elasticities in a
simple way by modifying script inputs read in by the Patient Module,
using estimates on price elasticity provided by Medicines Australia.
Such price responses could be built into the model if appropriate data
were available. The price responses could be estimated differentiating
between drug groups, concessional and general patients, the price
responses one year after the change in price or copayment and the
responses for longer periods thereafter. If such price responses were
built into the model, care should be taken that the price responses are
not overstated or double counted in cases of drugs dropping out when
the average drug price falls below copayment levels.
Broadening the focus of the model to cover all prescribed drugs
The original model focused on only PBS prescribed drugs. As previously
stated, if some drugs dropped out of the PBS the associated scripts and
costs for those drugs were not counted in. Several of the scenarios were
likely to lead to a number of drug groups dropping out of the model, as
costs for general patients fell below proposed copayment levels. To
retain these drug groups in the model and to be able to identify related
script numbers and costs, NATSEM built into the model, in addition to
the expenditure buckets for government expenditure and patient
copayments, a third bucket that would pick up the patient expenditure
on these particular PBS drugs whose prices were below the copayment.
The third bucket was constructed by retaining all scripts and costs even
when the average cost of some drugs fell below the proposed
copayment, with a flag variable created to distinguish between costs and
scripts falling within and outside the scope of the PBS. The models
standard output presents total scripts, patient costs and government
costs (regardless of whether these fall within or outside the PBS) by drug
type. The proportion of total scripts and costs falling outside the PBS is
indicated at the end of the table. Additional tables presenting scripts and
costs (number and percentage to total scripts and costs) by drug type for
drugs out of the PBS may also be generated.
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If the scope of the model were to be expanded to cover below copayment
drugs (Group 2 scripts) and private medicines (Group 3 scripts) then the
utility of the model would be enhanced and issues such as those
described above avoided. Further, including these medicines would give
a more complete picture of total expenditure on medicines by patients.
We currently have data on only the volume and the value of PBS
prescribed drugs. This phase of the work would require other data
sources such as the Australian Statistics on Medicines and/or the IMS
warehouse data of the pharmaceuticals industry. Considerable
benchmarking and adjustments would need to be made to match this
industry data with HIC data on prescribed drugs.
7.3 Major advancement  adding a health outcomes module
To date, the primary utility of the model has been based on its capability
to generate PBS expenditures based on various price and copayment
assumptions, as well as to estimate the corresponding effect on families
belonging to various income groups. While the model has provided
valuable insights into the effects of various policies on government
expenditure on PBS medicines and equity, it does not have the capability
to quantify the value that pharmaceutical spending delivers. To present
a more comprehensive picture of the contribution of pharmaceuticals to
the economy, the model needs to present not only the costs but also the
benefits of pharmaceuticals, particularly the improved health outcomes.
This is the purpose of the three-year industry partner grant that was
mentioned in section 1.
This extension will be more complex and resource intensive than the
modelling attempted to date. Modelling health outcomes presents a
range of theoretical and practical challenges (see, for example, McManus
et al. 1996, p. 392), particularly at the high level of aggregation at which
the MA model currently operates. There are limitations in the
methodology and data available for health outcomes modelling, which
will need to be explored and overcome in extending the model.
The introduction of diseases into the models dataset would be the
necessary first step to developing a facility in the model to measure
health outcomes. Adding variables on disease patterns to the model
would complement the variables already available on drug usage and
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cost patterns. This would enable us to examine, for example, options that
raise copayment thresholds for general patients but simultaneously
protect the chronically ill through safety net provisions.
For various reasons, the existing Patient Module produces adequate
aggregate estimates, but the usage of pharmaceuticals as imputed onto
the person-level dataset is not based on actual disease patterns, and the
patterns of drug usage for individuals are not in accordance with disease
profiles and clinical practice. We need to overcome the current clinical
inconsistency in the allocation of multiple drugs to individual users, and
to ensure that drug usage at the level of the individual matches disease
patterns in the model.
At this stage, the best way to add these enhancements to the Patient
Module appears to be to replace the existing Patient Module database
with the 2001 ABS NHS confidentialised unit record files, as these files
contain the latest person-level information on health conditions, drug
usage for priority conditions, and health risk factors. However, since the
2001 NHS contains less detail on prescribed drugs, it is not intended that
this be the sole basis of the enhanced Patient Module concerning drug
usage and health conditions. The 1995 NHS records will also be used to
effectively retrieve additional information for those who do not suffer
from priority diseases and/or do not have long-term health conditions.
The next step would be to quantify health outcomes. Since the feasibility
of actually incorporating a health outcomes module has not been fully
established, the approach would be to start off with a scoping study that
ultimately would identify a recommended approach for adding a health
outcomes module to the current MA model. This would involve an
extensive literature review, discussion with national and international
experts in health outcomes research, a workshop, an evaluation of
alternative measures of health outcomes and methods for assessing
health outcomes (for example, use of quality adjusted life years (QALYs),
disability adjusted years (DALYs) and cost-effectiveness ratios),
exploration of an appropriate microsimulation methodology, and
assessment of data requirements and possible data sources. QALYs and
DALYs could be estimated the same way as in the study of the burden of
disease undertaken by the Australian Institute of Health and Welfare
(Mathers, Vos and Stevenson 1999). An example of how DALYs can be
used as a health outcomes measure in a modelling context can be found
in Walker (2001).
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QALYs and DALYs are standard broad brush measures used in cross-
sectional studies by organisations such as the World Health Organization
and the Australian Institute of Health and Welfare. The scoping study,
however, may indicate that, while broad-brush measures are a good first
step, greater detail may be required for the model to accurately simulate
health outcomes for specific diseases or treatments. The accuracy of the
simulated health effects of drug use will depend on the degree of detail
available in the 1995 and 2001 NHS at the disease level.
The scoping study could also investigate the possibility of adding further
direct and indirect economic and social costs, such as other direct health
care costs, labour force participation (for example, early retirement) and
productivity (for example, absenteeism), school attendance and indirect
costs of caregiving.
Once a modelling approach has been developed, this could be piloted in
one of the models therapeutic areas and then rolled out to other selected
therapeutic areas. Candidate areas for the pilot would be chosen on the
basis of the ease of modelling outcomes and the availability of data.
Asthma and schizophrenia are possible candidates, but the choice of
therapeutic class would need to be based on the outcomes of the scoping
paper and discussion and agreement between Medicines Australia and
NATSEM.
The pilot would be developed initially outside of the main model, in
order to test the feasibility of a health outcomes module. However, the
data used in the pilot would mimic the data that would eventually be
generated by the model. Thus, once the new model has been completed,
the pilot could undergo testing within the model.
On completion, the health outcomes extension would ideally be able to
quantify the benefits that additional spending in different therapeutic
areas would deliver in terms of:
• reduced mortality
• reduced morbidity
• indirect savings to the health system
• indirect savings to the welfare system
• other social and economic benefits.
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The extension would enable the industry to show the desirability of
increased expenditure on pharmaceuticals, both in terms of health
benefits and relative to expenditure in other areas of health and welfare.
With health outcomes added to the model, it would be possible to
compare projected increases in PBS costs with the health benefits
expected from increased spending on medicines in terms of, for example,
the number of life years saved. Using the models outputs, it would also
be possible to assess the economic benefits of keeping patients
operational in terms of, for example, keeping their jobs rather than
receiving a government benefit, or living independently rather than
having a carer or going into a nursing home.
8 Summary and conclusions
This version of the microsimulation model that NATSEM developed for
Medicines Australia to model the distributional and other impacts of the
PBS has provided valuable insights into the effects of various policies on
government expenditure on PBS medicines and on patient equity. By
focusing the analysis on PBS costs, however, there is the risk of further
entrenching the cost containment mentality that currently dominates the
debate on PBS sustainability. The authors recognise the need to consider
not only the costs associated with pharmaceuticals, but also the
associated benefits such as continued access to new medicines in
Australia.
The opportunity to further improve the model was realised when late in
2001 NATSEM won a large three-year Australian Research Council
Linkage Grant for this purpose. The most important features of the
model that can be improved are in the areas of modelling the safety net,
using a distributional approach to drug pricing, expanding the scope of
the model to cover all prescribed pharmaceuticals rather than only PBS-
subsidised prescribed drugs, and quantifying the health benefits of
future pharmaceutical innovations.
The project will result in an immensely powerful model  that can be used
to help influence policy and public debate about pharmaceuticals and the
PBS.
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Examples of the types of policy question that could be analysed follow.
• What is the impact of expected changes in PBS-subsidised drug prices
and scripts over the next five to ten years on government PBS outlays,
on patient out-of-pocket expenditure and on related revenues to
industry?
• What is the likely impact of the introduction of new PBS listed drugs?
• What effects could demographic and socioeconomic changes have on
outlays on the PBS over the next five to ten years and on the costs to
consumers?
• What would be the distributional and revenue impacts of changes in
the rules of the PBS (for example, changes in copayment levels, the
introduction of differential copayment levels, and changes in
concessional eligibility rules or in certain drug-related PBS rules)?
More advanced questions could be addressed.
• Which diseases are the major contributors to the usage and cost
patterns observed for particular classes of prescribed drugs?
• What would be the cost and distributional impacts of changing the
safety net provisions of the current PBS scheme?
• How would pharmaceutical usage and costs respond to the earlier
onset of diseases expected from the significant increases in obesity
over the past five years among Australias children and young
adults?
• How would the introduction of a new drug able to control obesity
alter the above results?
• What would be the ranking of various future pharmaceutical policy
options in terms of their health benefits relative to their costs?
If Australia is to enjoy ongoing access to new medicines, the debate must
be broadened to consider the benefits that these medicines will bring.
Current trends, including the imminent introduction of new biotech-
nology therapies and the sharp increases in PBS outlays in recent years,
suggest that Medicines Australia and its members can expect growing
public attention to be focused on pharmaceuticals and the PBS in the
next few years. The proposed project offers Medicines Australia an
opportunity to begin extending the public debate to include the benefits
of improved health outcomes. Such an extension appears vital to the
future success of the pharmaceuticals industry in Australia.
A Microsimulation Model of the PBS: Version 00-01 51
NATSEM Technical Paper no. 30
A Classification of medications
Table A1 Drug concordance schedule
Drug
class Overall NHS class
NHS
class NHS description
ATC
code ATC description
1 Arthritis drugs 1 Anti-inflammatories M01A Anti-inflammatory and
antirheumatic products, non-
steroids
2 Asthma medications 5 Adrenergics R03A Adrenergics, inhalants
 6 Anti-asthmatics R03B Other anti-asthmatics,
inhalants
  7 Anti-asthmatics for
systemic use
R03D Other anti-asthmatics for
systemic use
3 Diabetes medications 8 Insulins A10A Insulins and analogues
  9 Blood glucose lowering
drugs
A10B Oral blood glucose lowering
drugs
4 12 Vasodilators C01D Vasodilators used in cardiac
diseases
  17 Beta blockers C07A Beta blocking agents
5 16 ACE inhibitors C09A ACE inhibitors, plain
    C09B ACE inhibitors, combinations
6 Angiotensin II
antagonists
C09C Angiotensin II antagonists,
plain
    C09D Angiotensin II antagonists,
combinations
7 18 Calcium channel
blockers
C08C Selective calcium channel
blockers with mainly vascular
effects
 C08D Selective calcium channel
blockers with direct cardiac
effects
 C08E Non-selective calcium
channel blockers
8 Serum lipid reducing
agents
24 Cholesterol and
triglyceride reducers
C10A Cholesterol and triglyceride
reducers
9 Analgesic medications 25 Opioids N02A Opioids
  26 Other analgesics N02B Other analgesics and
antipyretics
10 Psycholeptic
medications
27 Antipsychotics N05A Antipsychotics
11 28 Anxiolytics N05B Anxiolytics
  29 Hypnotics and sedatives N05C Hypnotics and sedatives
(Continued on next page)
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Table A1 Drug concordance schedule  (continued)
Drug
class Overall NHS class
NHS
class NHS description
ATC
code ATC description
12 Medications for
anxiety/depression/
nervous conditions
30 Antidepressants N06A Antidepressants
13 34 Stomach medications A01A Stomatological preparations
 A02A Antacids
 A02B Drugs for treatment of peptic
ulcer
    A02E Antiregurgitants
14 J01A Tetracyclines
 J01B Amphenicols
 J01C Beta-lactam antibacterials,
penicillins
 J01D Other beta-lactam
antibacterials
 J01E Sulfonamides and
trimethoprim
 J01F Macrolides and lincosamides
 J01G Aminoglycoside antibacterials
 J01M Quinolone antibacterials
    J01X Other antibacterials
15 L01A Alkylating agents
 L01B Antimetabolites
 L01C Plant alkaloids and other
natural products
 L01D Cytotoxic antibiotics and
related substances
 L01X Other antineoplastic agents
 L02A Hormones and related agents
 L02B Hormone antagonists and
related agents
 L03A Cytokines and
immunomodulators
    L04A Immunosuppressive agents
16 G01A Antiinfectives and antiseptics,
excl. comb. with
corticosteroids
 G02A Oxytocics
 G02C Other gynecologicals
 G03A Hormonal contraceptives for
systemic use
 G03B Androgens
 G03C Estrogens
 G03D Progestogens
 G03F Progestogens and estrogens
in combination
(Continued on next page)
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Table A1 Drug concordance schedule  (continued)
Drug
class Overall NHS class
NHS
class NHS description
ATC
code ATC description
 G03G Gonadotropins and other
ovulation stimulants
 G03H Antiandrogens
 G03X Other sex hormones and
modulators of the genital
system
 G04A Urinary antiseptics and
antiinfectives
    G04B Other urologicals, incl.
antispasmodics
17    N03A Antiepileptics
18    J05A Direct acting antivirals
19 Allergy drugs 3 Decongestants R01A Decongestants and other
nasal preparations for topical
use
 4 Antihistamines R06A Antihistamines for systemic
use
20 Heart and blood
pressure drugs
10 Cardiac glycosides C01A Cardiac glycosides
 11 Antiarrhythmics C01B Antiarrhythmics, class I and
III
21 13 Anti-adrenergics,
centrally acting
C02A Antiadrenergic agents,
centrally acting
14 Anti-adrenergics,
peripherally acting
C02C Antiadrenergic agents,
peripherally acting
 15 Muscles acting on
arteriolar smooth muscle
C02D Arteriolar smooth muscle,
agents acting on
22 Fluid/diuretic
medications
19 Low ceiling diuretics,
thiazides
C03A Low-ceiling diuretics,
thiazides
20 Low ceiling diuretics,
excl. thiazides
C03B Low-ceiling diuretics, excl.
thiazides
21 High ceiling diuretics C03C High-ceiling diuretics
22 Potassium-sparing
agents
C03D Potassium-sparing agents
 23 Diuretics/potassium-
sparing agents
C03E Diuretics and potassium-
sparing agents in combination
23 Other medications 31 Vitamin and mineral
supplements
A11C Vitamin A and D, incl.
combinations of the two
A11D Vitamin B1, plain and in
combination with vitamin B6
and vitamin B12
A11H Other plain vitamin
preparations
A12A Calcium
   A12B Potassium
(Continued on next page)
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Table A1 Drug concordance schedule  (continued)
Drug
class Overall NHS class
NHS
class NHS description
ATC
code ATC description
24 32 Cough and cold
medications
R05C Expectorants, excl.
combinations with cough
suppressants
R05D Cough suppressants, excl.
combinations with
expectorants
   R05X Other cold combination
preparations
25 33 Skin ointments and
creams
D Dermatologicals
D01A Antifungals for topical use
D01B Antifungals for systemic use
D02A Emollients and protectives
D04A Antipruritics, incl.
antihistamines, anesthetics
D05B Antipsoriatics for systemic
use
D06B Chemotherapeutics for topical
use
D07A Corticosteroids, plain
D08A Antiseptics and disinfectants
D10B Anti-acne preparations for
systemic use
   D11A Other dermatological
preparations
26  35 Laxatives A06A Laxatives
27 36 Other medication A03A Synthetic antispasmodic and
anticholinergic agents
A03B Belladonna and derivatives,
plain
A03F Propulsives
A04A Antiemetics and
antinauseants
A07A Intestinal anti-infectives
A07B Intestinal absorbents
A07C Electrolytes with
carbohydrates
A07D Antipropulsives
A07E Intestinal anti-inflammatory
agents
A09A Digestives, incl. enzymes
A14A Anabolic steroids
   A15 Appetite stimulants
(Continued on next page)
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Table A1 Drug concordance schedule  (continued)
Drug
class Overall NHS class
NHS
class NHS description
ATC
code ATC description
28 B01A Antithrombotic agents
B02A Antifibrinolytics
B03A Iron preparations
B03B Vitamin B12 and folic acid
B05A Blood and related products
   B05B I.V. solutions
29 H01A Anterior pituitary lobe
hormones and analogues
H01B Posterior pituitary lobe
hormones
H01C Hypothalamic hormones
H02A Corticosteroids for systemic
use, plain
H03A Thyroid preparations
H03B Antithyroid preparations
H04A Glycogenolytic hormones
   H05B Antiparathyroid hormones
30 J02A Antimycotics for systemic use
J04A Drugs for treatment of
tuberculosis
J06A Immune sera
J07A Bacterial vaccines
   J07B Viral vaccines
31  2 Antirheumatics M01C Specific antirheumatic agents
32 M02A Topical products for joint and
muscular pain
M03B Muscle relaxants, centrally
acting agents
M03C Muscle relaxants, directly
acting agents
M04A Antigout preparations
   M05B Drugs affecting mineralisation
33 N02C Antimigraine preparations
N04A Anticholinergic agents
N04B Dopaminergic agents
N06B Psychostimulants and
nootropics
   N07A Parasympathomimetics
34 P01A Agents against amoebiasis
and other protozoal diseases
P01B Antimalarials
P02C Antinematodal agents
P02D Anticestodals
   P03A Ectoparasiticides, incl.
scabicides
(Continued on next page)
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Table A1 Drug concordance schedule  (continued)
Drug
class Overall NHS class
NHS
class NHS description
ATC
code ATC description
35 S Sensory organs
S01A Anti-infectives
S01B Anti-inflammatory agents
S01E Antiglaucoma preparations
and miotics
S01F Mydriatics and cycloplegics
S01G Decongestants and anti-
allergics
S01H Local anesthetics
S01X Other ophthalmologicals
S02A Anti-infectives
S02C Corticosteroids and anti-
infectives in combination
S03A Anti-infectives
   S03B Corticosteroids
36 C01C Cardiac stimulants excl.
cardiac glycosides
C04A Peripheral vasodilators
C05A Antihemorrhoidals for topical
use
R03C Adrenergics for systemic use
V01A Allergens
V03A All other therapeutic products
V04B Urine tests
V04C Other diagnostic agents
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B Patient Module base year input data
Table B1 Script numbers by the 36 drug classes and patient category, 2000-01
Drug
class
Concessional
 above SNT
(C0)
Concessional
 below SNT
(C1)
Total
concessional
scripts
Proportion of
concessional
scripts
General
 above SNT
(G1)
General
 below SNT
(G2)
Total
general
scripts
Proportion of
general
scripts
Total
scripts
Proportion of
total scripts
no. no. no. % no. no. no. % no. %
1 1 078 454 4 546 339 5 624 793 4.53 190 203 928 984 1 119 187 4.93 6 743 980 4.59
2 2 024 189 5 688 039 7 712 228 6.21 354 277 1 737 372 2 091 649 9.22 9 803 877 6.68
3 867 842 2 566 764 3 434 606 2.77 198 426 176 571 374 997 1.65 3 809 603 2.59
4 1 405 126 4 624 521 6 029 647 4.86 202 165 107 677 309 842 1.37 6 339 489 4.32
5 1 318 637 5 970 369 7 289 006 5.87 338 415 2 401 507 2 739 922 12.08 10 028 928 6.83
6 484 472 2 340 017 2 824 489 2.28 144 447 1 360 272 1 504 719 6.63 4 329 208 2.95
7 1 223 532 4 814 566 6 038 098 4.86 286 475 1 062 239 1 348 714 5.95 7 386 812 5.03
8 1 535 690 6 395 084 7 930 774 6.39 405 035 2 976 791 3 381 826 14.91 11 312 600 7.71
9 2 372 917 6 641 901 9 014 818 7.26 142 095 92 252 234 347 1.03 9 249 165 6.30
10 300 102 1 584 828 1 884 930 1.52 33 254 109 148 142 402 0.63 2 027 332 1.38
11 1 507 428 4 791 267 6 298 695 5.07 103 128 17 537 120 665 0.53 6 419 360 4.37
12 1 140 317 5 364 265 6 504 582 5.24 229 114 2 759 973 2 989 087 13.18 9 493 669 6.47
13 1 727 578 5 584 677 7 312 255 5.89 274 008 1 747 682 2 021 690 8.91 9 333 945 6.36
14 1 192 872 9 599 295 10 792 167 8.69 252 763 242 226 494 989 2.18 11 287 156 7.69
15 103 932 476 649 580 581 0.47 34 609 272 043 306 652 1.35 887 233 0.60
16 741 319 4 941 274 5 682 593 4.58 274 793 319 129 593 922 2.62 6 276 515 4.28
17 133 840 940 287 1 074 127 0.87 28 765 323 415 352 180 1.55 1 426 307 0.97
18 9 079 92 377 101 456 0.08 3 945 170 919 174 864 0.77 276 320 0.19
19 140 263 439 798 580 061 0.47 23 638 68 092 91 730 0.40 671 791 0.46
20 219 682 665 403 885 085 0.71 28 124 68 703 96 827 0.43 981 912 0.67
21 155 127 545 927 701 054 0.56 30 830 56 662 87 492 0.39 788 546 0.54
22 618 193 1 919 659 2 537 852 2.04 90 008 24 005 114 013 0.50 2 651 865 1.81
(Continued on next page)
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Table B1 Script numbers by the 36 drug classes and patient category, 2000-01  (continued)
Drug
class
Concessional
 above SNT
(C0)
Concessional
 below SNT
(C1)
Total
concessional
scripts
Proportion of
concessional
scripts
General
 above SNT
(G1)
General
 below SNT
(G2)
Total
general
scripts
Proportion of
general
scripts
Total
scripts
Proportion of
total scripts
no. no. no. % no. no. no. % no. %
23 342 741 992 643 1 335 384 1.08 26 432 40 238 66 670 0.29 1 402 054 0.96
24 73 266 255 596 328 862 0.26 4 844 2 727 7 571 0.03 336 433 0.23
25 422 897 2 206 802 2 629 699 2.12 55 689 252 926 308 615 1.36 2 938 314 2.00
26 154 446 395 886 550 332 0.44 7 035 7 041 14 076 0.06 564 408 0.38
27 405 873 1 242 027 1 647 900 1.33 67 714 308 723 376 437 1.66 2 024 337 1.38
28 825 368 2 540 795 3 366 163 2.71 86 142 116 764 202 906 0.89 3 569 069 2.43
29 428 829 1 565 162 1 993 991 1.61 85 677 86 403 172 080 0.76 2 166 071 1.48
30 23 771 689 787 713 558 0.57 5 960 46 950 52 910 0.23 766 468 0.52
31 3 942 10 779 14 721 0.01 1 194 6 116 7 310 0.03 22 031 0.02
32 297 134 1 053 268 1 350 402 1.09 56 498 89 502 146 000 0.64 1 496 402 1.02
33 229 382 884 219 1 113 601 0.90 61 275 88 730 150 005 0.66 1 263 606 0.86
34 211 277 752 089 963 366 0.78 23 618 30 978 54 596 0.24 1 017 962 0.69
35 1 311 243 4 881 129 6 192 372 4.99 115 049 165 936 280 985 1.24 6 473 357 4.41
36 261 077 825 833 1 086 910 0.88 28 978 125 385 154 363 0.68 1 241 273 0.85
All 25 291 837 98 829 321 124 121 158 100.00 4 294 622 18 391 618 22 686 240 100.00 146 807 398 100.00
Source: HIC.
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Table B2 Government, patient and total costs by the 36 drug classes and patient category, 2000-01
Drug
class
Govt
cost
(C0)
Patient
cost
(C0)
Total
cost
(C0)
Govt
cost
(C1)
Patient
cost
(C1)
Total
cost
(C1)
Govt
cost
(G1)
Patient
cost
(G1)
Total
cost
(G1)
Govt
cost
(G2)
Patient
cost
(G2)
Total
cost
(G2) Total
$ $ $ $ $ $ $ $ $ $ $ $ $
1  38 168 775  0  38 168 775  128 085 984  15 512 487  143 598 471  5 739 493  640 868  6 380 361  29 440 123  19 891 163  49 331 286  237 478 893
2  69 831 348  0  69 831 348  155 351 389  19 373 660  174 725 049  34 111 065  3 592 598  37 703 663  36 374 697  36 886 391  73 261 088  355 521 148
3  26 496 823  0  26 496 823  72 875 760  8 762 520  81 638 280  6 032 227  667 304  6 699 531  24 535 962  3 757 750  28 293 712  143 128 347
4  25 574 196  0  25 574 196  57 010 116  15 773 071  72 783 187  2 897 455  679 896  3 577 351  2 737 442  2 294 858  5 032 300  106 967 034
5  38 422 659  0  38 422 659  148 561 506  20 349 359  168 910 865  9 166 410  1 137 903  10 304 313  20 539 785  51 018 521  71 558 306  289 196 143
6  14 058 364  0  14 058 364  59 419 873  7 997 892  67 417 765  3 804 161  486 144  4 290 305  10 467 379  29 015 855  39 483 234  125 249 668
7  30 351 551  0  30 351 551  100 560 507  16 406 724  116 967 231  6 415 989  962 934  7 378 923  8 596 817  22 508 697  31 105 514  185 803 219
8  89 305 238  0  89 305 238  345 905 604  21 822 874  367 728 478  23 018 965  1 362 427  24 381 392  112 692 279  63 397 492  176 089 771  657 504 879
9  31 364 263  0  31 364 263  52 251 127  22 654 110  74 905 237  2 936 404  477 107  3 413 511  3 487 360  1 971 045  5 458 405  115 141 416
10  12 279 815  0  12 279 815  115 959 984  5 398 589  121 358 573  1 538 595  111 729  1 650 324  16 690 649  2 325 261  19 015 910  154 304 621
11  10 207 034  0  10 207 034  16 855 838  16 347 078  33 202 916  441 894  346 103  787 997  156 169  373 142  529 311  44 727 258
12  30 182 637  0  30 182 637  179 548 272  18 302 096  197 850 368  7 159 489  770 164  7 929 653  92 014 099  58 816 374  150 830 473  386 793 132
13  65 111 630  0  65 111 630  195 051 809  19 051 827  214 103 636  11 768 875  921 081  12 689 956  53 789 880  36 968 034  90 757 914  382 663 136
14  18 745 380  0  18 745 380  97 835 181  32 572 045  130 407 226  3 653 761  846 875  4 500 636  10 386 681  5 130 302  15 516 983  169 170 225
15  22 195 987  0  22 195 987  133 619 710  1 624 328  135 244 038  9 508 418  116 476  9 624 894  98 295 997  5 790 789  104 086 786  271 151 705
16  15 927 910  0  15 927 910  79 180 616  16 825 036  96 005 652  4 116 174  925 301  5 041 475  11 918 937  6 782 176  18 701 113  135 676 149
17  6 903 314  0  6 903 314  51 198 104  3 201 409  54 399 513  1 752 927  96 942  1 849 869  12 753 257  6 872 675  19 625 932  82 778 627
18  2 091 974  0  2 091 974  20 564 431  314 577  20 879 008  932 160  13 269  945 429  35 265 603  3 635 178  38 900 781  62 817 192
19  2 490 034  0  2 490 034  6 453 778  1 460 090  7 913 868  370 733  78 207  448 940  112 335  1 402 736  1 515 071  12 367 912
20  3 926 174  0  3 926 174  9 405 416  2 268 390  11 673 806  553 383  94 567  647 950  1 060 969  1 463 041  2 524 010  18 771 940
21  2 680 222  0  2 680 222  7 706 584  1 859 035  9 565 619  493 923  103 718  597 641  313 916  1 204 247  1 518 163  14 361 645
22  6 816 289  0  6 816 289  16 399 233  6 538 935  22 938 168  896 997  302 997  1 199 994  375 642  510 116  885 758  31 840 209
23  8 028 680  0  8 028 680  20 826 192  3 382 916  24 209 108  669 981  88 888  758 869  1 697 442  855 758  2 553 200  35 549 857
24  941 492  0  941 492  2 194 288  865 890  3 060 178  53 448  16 208  69 656  30 622  57 975  88 597  4 159 923
25  5 823 304  0  5 823 304  30 734 179  7 510 703  38 244 882  1 135 326  187 447  1 322 773  26 808 866  5 365 580  32 174 446  77 565 405
26  2 766 544  0  2 766 544  5 832 119  1 351 788  7 183 907  109 572  23 623  133 195  42 229  149 173  191 402  10 275 048
(Continued on next page)
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Table B2 Government, patient and total costs by the 36 drug classes and patient category, 2000-01  (continued)
Drug
class
Govt
cost
(C0)
Patient
cost
(C0)
Total
cost
(C0)
Govt
cost
(C1)
Patient
cost
(C1)
Total
cost
(C1)
Govt
cost
(G1)
Patient
cost
(G1)
Total
cost
(G1)
Govt
cost
(G2)
Patient
cost
(G2)
Total
cost
(G2) Total
$ $ $ $ $ $ $ $ $ $ $ $ $
27  9 964 874  0  9 964 874  27 776 024  4 228 104  32 004 128  2 629 615  227 366  2 856 981  15 462 002  6 543 812  22 005 814  66 831 797
28  15 037 711  0  15 037 711  41 754 610  8 663 040  50 417 650  1 795 431  289 870  2 085 301  10 723 006  2 492 783  13 215 789  80 756 451
29  4 113 028  0  4 113 028  12 300 656  5 330 479  17 631 135  607 217  288 417  895 634  2 533 378  1 835 508  4 368 886  27 008 683
30  1 964 810  0  1 964 810  16 505 547  2 397 437  18 902 984  710 189  20 177  730 366  2 441 449  1 009 641  3 451 090  25 049 250
31  264 373  0  264 373  685 059  36 744  721 803  69 587  4 015  73 602  276 143  129 965  406 108  1 465 886
32  9 472 049  0  9 472 049  34 111 065  3 592 598  37 703 663  1 222 805  190 306  1 413 111  4 290 619  1 909 165  6 199 784  54 788 607
33  7 678 024  0  7 678 024  24 087 500  3 014 790  27 102 290  1 700 484  206 002  1 906 486  2 806 307  1 888 891  4 695 198  41 381 998
34  2 296 393  0  2 296 393  5 565 920  2 564 716  8 130 636  242 146  79 458  321 604  453 548  658 780  1 112 328  11 860 962
35  19 541 494  0  19 541 494  52 076 272  16 643 088  68 719 360  1 555 896  386 789  1 942 685  2 377 430  3 531 025  5 908 455  96 111 994
36  9 260 918  0  9 260 918  35 359 926  2 812 935  38 172 861  1 344 019  97 534  1 441 553  10 147 589  2 665 086  12 812 675  61 688 007
All  660 285 311  0  660 285 311  2 359 610 179  336 811 362  2 696 421 541  151 155 214  16 840 707 167 995 921  662 096 608  391 108 985  1 053 205 593  4 577 908 365
Source: HIC.
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C Key variables in the model
Table C1 Key variables in the MA model
Variable Description
AGEFAMHD Age group of head of family:
2 1539 years
3 4064 years
4 6574 years
5 75 + years
AGE_GRP Broad age groupings:
1 014 years
2 1539 years
3 4064 years
4 6574 years
5 75 + years
AGE_PBS Age groupings in 5-year intervals:
1 04 years
2 59 years
3 1014 years
4 1519 years
5 2024 years
6 2529 years
7 3034 years
8 3539 years
9 4044 years
10 4549 years
11 5054 years
12 5559 years
13 6064 years
14 6569 years
15 7074 years
16 75+ years
AVPC [1-37] Average total cost of PBS drugs  concessional patients (Group 1) (= C0 + C1 +
G1)
AVPG [1-37] Average total cost of PBS Group 1 drugs above copayment prior to simulations 
general patients (= G2)
CARD Card status  indicates eligibility to the PBS concessions (from CSHCCARD,
HCCARD and PCCARD subcomponents)
0 No card
1 Yes card
CLASS Card status
0 PBS general patients
1 PBS concessional patients
DISPINCU Weekly disposable income of the family (income unit)
(Continued on next page)
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Table C1 Key variables in the MA model  (continued)
Variable Description
DRGCOUNT Number of Group 1 drugs used by each person over the two week survey period
DR[1-37] Scripts totals for last 12 months of the simulations (ie 2000-01 for the base case)
by drug type for both concessional and general patients
DTYPE[1-37] Type of drug prescribed to each patient (eg DTPYE 3 will be 1 for each patient
using diabetes medications)
1 Anti-inflammatories
2 Anti-asthmatics
3 Diabetes medications
4 Vasodilators and beta blockers
5 ACE inhibitors
6 Angiotensin IIs
7 Calcium channel blockers
8 Cholesterol and triglyceride reducers
9 Analgesic medications
10 Antipsychotics
11 Anxiolytics and hypnotics
12 Antidepressants
13 Stomach medications
14 Antibiotics
15 Antineoplastics
16 Genitourinary
17 Anti-epileptics
18 Direct acting antivirals
19 Decongestants and antihistamines
20 Cardiac glycosides and antiarrhythmics
21 Antihypertensives
22 Fluid and diuretic medications
23 Vitamin and mineral supplements
24 Cough and cold medications
25 Skin ointments and creams
26 Laxatives
27 Other medication  alimentary tract & metabolic (excl. diabetes & stomach
medications)
28 Other medication  blood and blood forming organs
29 Other medication  systemic hormonal preparations (excluding sex
hormones)
30 Other medication  general antiinfectives (excluding antibacterials antivirals)
31 Specific antirheumatic agents
32 Other muscoskeletal medication  topical products, muscle relaxants, anti-
gout & bone disease
33 Other medication  antimigraine psychostimulants & nootropics, anti-
Parkinsons & parasympathomimetics
34 Other medication  antiparasitic products, insecticides and repellents
35 Other medication  sensory organs
36 Other medication  various
(+37) *
DTP1-DTP1443 Drug type by individual over time
(Continued on next page)
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Table C1 Key variables in the MA model  (continued)
Variable Description
FAMTYPE Family type
1 Married couple, no dependants
2 Married couple, with dependants
3 Sole parent
4 Single taxpayer
FAMSIZE Number of persons in each income unit (average)
GOV Government cost over last 12 months of simulation  concessional and general
patients
GOVDR [1-37] Government cost totals for last 12 months of the simulations (ie 2000-01 for the
base case) by drug type for both concessional and general patients
GROUP Groups of drugs falling within and outside the PBS
1 For PBS drugs which attract a government subsidy
2 For PBS drugs with below copayment charges prior to simulations (of
relevance mainly to general patients)
3 For prescribed drugs not under the PBS.
INC_ID Income unit identification number, common to all members of a family
PAT Patient expenditures over last 12 months of simulation  concessional and
general patients
PATDR [1-37] Patient contribution totals for last 12 months of the simulations (ie 1996-97 for the
base case) by drug type for both concessional and general patients
PERS_ID Unique identification number for each person
SEX Sex of person:
1 Male
2 Female
SEXFAMHD Sex of family head:
1 Male
2 Female
SUMCP27 Spending by families on Group 1 drugs in the two weeks 114 January 2001
(concessional and general)
TGC1 to
TGC1443
Government costs over time, by drug and by individual  concessional patients
TGG1 to
TGG1443
Government costs over time, by drug and by individual  general patients
TPC1 to TPC1443 Patient contributions over time, by drug and by individual  concessional patients
TPG1 to
TPG1443
Patient contributions over time, by drug and by individual  general patients
WTP Weight of person (or family)
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